Contrast agents for applications including perfusion imaging

ABSTRACT

The present invention is directed, in part, to compounds and methods for imaging the central nervous system or cancer, comprising administering to a subject a contrast agent which comprises a compound that binds MC-I, and an imaging moiety, and scanning the subject using diagnostic imaging.

RELATED APPLICATIONS

This application claims priority under 35 U.S.C. §119(e) to co-pendingU.S. Provisional Application Ser. No. 61/067,593, filed Feb. 29, 2008,the contents of which are incorporated herein by reference.

FIELD OF THE INVENTION

The present invention relates to compounds comprising imaging moieties,and their use in imaging and/or diagnosing certain disorders in asubject.

BACKGROUND OF THE INVENTION

Mitochondria are membrane-enclosed organelles distributed through thecytosol of most eukaryotic cells. Mitochondria levels are elevated intissues that require greater energy to function. Examples of such tissueinclude brain, central nervous system, and cancerous tissues.

Complex 1 (“MC-1”) is a membrane-bound protein complex of 46 dissimilarsubunits. This enzyme complex is one of three energy-transducingcomplexes that constitute the respiratory chain in mammalianmitochondria. This NADH-ubiquinone oxidoreductase is the point of entryfor the majority of electrons that traverse the respiratory chain,eventually resulting in the reduction of oxygen to water (Q. Rev.Biophys. 1992, 25, 253-324).

Known inhibitors of MC-1 include deguelin, piericidin A, ubicidin-3,rolliniastatin-1, rolliniastatin-2 (bullatacin), capsaicin, pyridaben,fenpyroximate, amytal, MPP+, quinolines, and quinolones (BBA 1998, 1364,222-235).

Previous work has shown that ¹⁸F-fluorodeoxyglucose (FDG) may be usefulin imaging cancer in a subject. For example elevated demand by tissuesfor energy can preferentially retain ¹⁸F-fluorodeoxyglucose in cancercells. However, due to the mechanism of uptake for¹⁸F-fluorodeoxyglucose, not all cancers are “PET active,” in the use ofFDG.

SUMMARY OF THE INVENTION

The present invention relates to the recognition that interrupting thenormal function of mitochondria may advantageously concentrate certaincompounds in the mitochondria, and, hence, in mitochondria-rich tissue.As described herein, such compounds may be labeled with at least oneimaging moiety, such that mitochondrial build-up may be determined,thereby providing valuable diagnostic markers for brain and cancerimaging. For purposes of this specification, a compound is referred toas “labeled” when an imaging moiety is attached to (e.g. bound to) thecompound.

In some embodiments, the present invention provides methods of imagingat least a portion of the brain (e.g., brain tissue), central nervoussystem, or a cancer, comprising administering to a subject a contrastagent which comprises an imaging moiety and a compound bound to theimaging moiety, the compound selected from pyridaben, fenazaquin, apyridaben analog, a pyridimifen analog, a tebufenpyrad analog, and anfenazaquin analog; and scanning the subject using diagnostic imaging toproduce an image of at least a portion of the brain, central nervoussystem (CNS), or a cancer (e.g., a non-CNS cancer). The image may beused in the diagnosis of a subject, or to determine the stage of adisease.

In some embodiments, the present invention provides a contrast agentcomprising an imaging moiety and a compound bound to the imaging moiety,the compound selected from pyridaben, fenazaquin, a pyridaben analog, apyridimifen analog, a tebufenpyrad analog, and a fenazaquin analog. Insome embodiments, the present invention provides a contrast agentcomprising an imaging moiety and a compound bound to the imaging moiety,the compound selected from pyridaben, fenazaquin, a pyridaben analog,and a fenazaquin analog. In some embodiments, the imaging moiety is aradioisotope for nuclear medicine imaging.

In some embodiments, the radioisotope for nuclear medicine imaging is¹¹C, ¹³N, ¹⁸F, ¹²³I, ¹²⁵I. In one set of embodiments, the imaging moietyis ¹⁸F.

In some embodiments, the contrast agent comprises an imaging moiety anda compound bound to the imaging moiety, the compound selected frompyridaben, fenazaquin, a deguelin analog, a pyridaben analog, apyridimifen analog, a tebufenpyrad analog, and a fenazaquin analogwherein the contrast agent has a structure as in Formula (I),

wherein:

G is

m is 0 or 1;

and

each independently represent a single or a double bond;

R²⁷, R³⁰, R³¹, R³², R³³, and R³⁴ are independently selected fromhydrogen, alkyl, optionally substituted, and an imaging moiety;

R²⁸, when present, is selected from hydrogen and alkyl, optionallysubstituted, provided that when

is a double bond, R²⁸ is absent;

R²⁹, when present, is alkyl, optionally substituted, provided that when

is a double bond, R²⁹ is absent;

P is

wherein R³⁵, R³⁶, R³⁷, R³⁸, and R³⁹ are independently selected fromhydrogen, alkyl, optionally substituted, and an imaging moiety;

P′, when present, is hydrogen, provided that when

is a double bond, P′ is absent;

or, P and P′ together form an oxo group;

Q is halo or haloalkyl;

J is selected from N(R²⁷), S, O, C(═O), C(═O)O, NHCH₂CH₂O, a bond, andC(═O)N(R²⁷);

K and L, when present, are independently selected from hydrogen,alkoxyalkyl, alkyloxy, aryl, alkyl, heteroaryl, and an imaging moiety,each of which is optionally substituted;

M is selected from hydrogen, alkoxyalkyl, alkyloxy, aryl, alkyl,heteroaryl, and an imaging moiety, each of which is optionallysubstituted, or

L and M, together with the atom to which they are attached, form a ring,optionally substituted;

n is 0, 1, 2, or 3;

R²¹, R²², R²³, R²⁴, R²⁵, and R²⁶ are independently selected fromhydrogen, alkyl, optionally substituted, and an imaging moiety, each ofwhich is optionally substituted; and

Y is selected from a bond, carbon, and oxygen; provided that when Y is abond, K and L are absent and M is selected from aryl and heteroaryl,each of which is optionally substituted; and provided that when Y isoxygen, K and L are absent and M is selected from hydrogen, alkoxyalkyl,aryl, alkyl, and heteroaryl, each of which is optionally substituted,

wherein at least one imaging moiety is present in Formula (I).

In one set of embodiments, K and L, when present, are independentlyselected from hydrogen, alkoxyalkyl, alkyloxy, aryl, heteroaryl, and animaging moiety, each of which is optionally substituted. In one set ofembodiments, M is selected from hydrogen, alkoxyalkyl, alkyloxy, aryl,heteroaryl, and an imaging moiety, each of which is optionallysubstituted. In one set of embodiments, L and M, together with the atomto which they are attached, form a three- or four-membered carbocyclicring, optionally substituted.

In one set of embodiments, J is selected from N(R²⁷), S, O, C(═O),C(═O)O, NHCH₂CH₂O, a bond, and C(═O)N(R²⁷), provided that, when J isC(═O)O, the carbon atom of J is attached to G and the oxygen atom of Jis attached to the carbon substituted with R²¹ and R²²; when J isNHCH₂CH₂O, the nitrogen atom of J is attached to G and the oxygen atomof J is attached to the carbon substituted with R²¹ and R²²; and, when Jis C(═O)N(R²⁷), the carbon atom of J is attached to G and the nitrogenatom of J is attached to the carbon substituted with R²¹ and R²².

In one set of embodiments, R²⁹ is C₁-C₆ alkyl. For example, C₁-C₆ alkylmay be tert-butyl.

In one set of embodiments, R²⁸ is C₁-C₆ alkyl. For example, C₁-C₆ alkylmay be methyl.

In any of the foregoing embodiments, any group may be optionallysubstituted with an imaging moiety. In some embodiments, K, L, or M areindependently alkoxyalkyl, alkyloxy, aryl, or heteroaryl, optionallysubstituted with an imaging moiety. In one set of embodiments, K, L, orM are independently alkoxyalkyl, optionally substituted with an imagingmoiety.

In one set of embodiments, M is alkoxyalkyl, optionally substituted withan imaging moiety.

In some embodiments, the contrast agent comprises an imaging moiety anda compound bound to the imaging moiety, the compound selected fromdeguelin, pyridaben, pyridimifen, tebufenpyrad, fenazaquin, a deguelinanalog, a pyridaben analog, a pyridimifen analog, a tebufenpyrad analog,and an fenazaquin analog wherein the contrast agent has a structure asin Formula (II),

wherein:

J is selected from N(R²⁷), S, O, C(═O), C(═O)O, NHCH₂CH₂O, a bond, orC(═O)N(R²⁷);

K and L, when present, are independently selected from hydrogen,alkoxyalkyl, alkyloxy, aryl, alkyl, heteroaryl, and an imaging moiety,each of which is optionally substituted;

M is selected from hydrogen, alkoxyalkyl, alkyloxy, aryl, alkyl,heteroaryl, and an imaging moiety, each of which is optionallysubstituted, or

L and M, together with the atom to which they are attached, form a ring,optionally substituted;

Q is halo or haloalkyl;

n is 0, 1, 2, or 3;

R²¹, R²², R²³, R²⁴, R²⁵, R²⁶, and R²⁷ are independently selected fromhydrogen, alkyl, optionally substituted, and an imaging moiety;

R²⁹ is alkyl, optionally substituted; and

Y is selected from a bond, carbon, and oxygen; provided that when Y is abond, K and L are absent and M is selected from aryl and heteroaryl,each of which is optionally substituted; and provided that when Y isoxygen, K and L are absent and M is selected from hydrogen, alkoxyalkyl,aryl, alkyl, and heteroaryl, each of which is optionally substituted,

wherein at least one imaging moiety is present in Formula (II).

In one set of embodiments, K and L, when present, are independentlyselected from hydrogen, alkoxyalkyl, alkyloxy, aryl, heteroaryl, and animaging moiety, each of which is optionally substituted. In one set ofembodiments, M is selected from hydrogen, alkoxyalkyl, alkyloxy, aryl,heteroaryl, and an imaging moiety, each of which is optionallysubstituted. In one set of embodiments, L and M, together with the atomto which they are attached, form a three- or four-membered carbocyclicring, optionally substituted.

In one set of embodiments, J is selected from N(R²⁷), S, O, C(═O),C(═O)O, NHCH₂CH₂O, a bond, and C(═O)N(R²⁷), provided that, when J isC(═O)O, the carbon atom of J is attached to G and the oxygen atom of Jis attached to the carbon substituted with R²¹ and R²²; when J isNHCH₂CH₂O, the nitrogen atom of J is attached to G and the oxygen atomof J is attached to the carbon substituted with R²¹ and R²²; and, when Jis C(═O)N(R²⁷), the carbon atom of J is attached to G and the nitrogenatom of J is attached to the carbon substituted with R²¹ and R²².

In one set of embodiments, J is O and R²⁹ is C₁-C₆ alkyl. For example,C₁-C₆ alkyl may be tert-butyl.

In any of the foregoing embodiments, any group may be optionallysubstituted with an imaging moiety. In some embodiments, K, L, or M areindependently alkoxyalkyl, alkyloxy, aryl, or heteroaryl, optionallysubstituted with an imaging moiety. In one set of embodiments, K, L, orM are independently alkoxyalkyl, optionally substituted with an imagingmoiety.

In one set of embodiments, M is alkoxyalkyl, optionally substituted withan imaging moiety.

In one set of embodiments, the contrast agent is selected from thefollowing group:

In a particular embodiment, the contrast agent is

In some embodiments, the contrast agent comprises an imaging moiety anda compound bound to the imaging moiety, the compound selected fromdeguelin, pyridaben, pyridimifen, tebufenpyrad, fenazaquin a deguelinanalog, a pyridaben analog, a pyridimifen analog, a tebufenpyrad analog,and an fenazaquin analog wherein the contrast agent has a structure asin Formula (III),

wherein:

J is selected from N(R²⁷), S, O, C(═O), C(═O)O, NHCH₂CH₂O, a bond, andC(═O)N(R²⁷);

K is selected from hydrogen, alkoxyalkyl, alkyloxy, aryl, alkyl,heteroaryl, and an imaging moiety, each of which is optionallysubstituted;

L, when present, is selected from hydrogen, alkoxyalkyl, alkyloxy, aryl,alkyl, heteroaryl, and an imaging moiety, each of which is optionallysubstituted;

M, when present, is selected from hydrogen, alkoxyalkyl, alkyloxy, aryl,alkyl, heteroaryl, and an imaging moiety, each of which is optionallysubstituted, or

L and M, together with the atom to which they are attached, form a ring,optionally substituted;

T and U are independently selected from hydrogen, alkoxy, alkoxyalkyl,alkyl, halo, and an imaging moiety, each of which is optionallysubstituted or, T and U, together with the carbon atoms to which theyare attached, form a five- to six-membered aromatic or non-aromatic ringcontaining zero to two heteroatoms selected from oxygen, nitrogen, andsulfur, wherein said ring is optionally substituted with one, two, orthree substituents independently selected from alkyl, optionallysubstituted, and an imaging moiety;

n is 0, 1, 2, or 3; and

R²¹, R²², R²³, R²⁴, R²⁵, R²⁶, R²⁷, and R³⁴ are independently selectedfrom hydrogen, alkyl, optionally substituted, and an imaging moiety; and

Y is selected from a bond, carbon, and oxygen, provided that when Y is abond, K and L are absent and M is selected from aryl and heteroaryl,each of which is optionally substituted; and provided that when Y isoxygen, K and L are absent and M is selected from hydrogen, alkoxyalkyl,aryl, alkyl, and heteroaryl, each of which is optionally substituted,

wherein at least one imaging moiety is present in Formula (III).

In one set of embodiments, K and L, when present, are independentlyselected from hydrogen, alkoxyalkyl, alkyloxy, aryl, heteroaryl, and animaging moiety, each of which is optionally substituted. In one set ofembodiments, M is selected from hydrogen, alkoxyalkyl, alkyloxy, aryl,heteroaryl, and an imaging moiety, each of which is optionallysubstituted. In one set of embodiments, L and M, together with the atomto which they are attached, form a three- or four-membered carbocyclicring, optionally substituted.

In one set of embodiments, J is selected from N(R²⁷), S, O, C(═O),C(═O)O, NHCH₂CH₂O, a bond, and C(═O)N(R²⁷), provided that, when J isC(═O)O, the carbon atom of J is attached to G and the oxygen atom of Jis attached to the carbon substituted with R²¹ and R²²; when J isNHCH₂CH₂O, the nitrogen atom of J is attached to G and the oxygen atomof J is attached to the carbon substituted with R²¹ and R²²; and, when Jis C(═O)N(R²⁷), the carbon atom of J is attached to G and the nitrogenatom of J is attached to the carbon substituted with R²¹ and R²².

In one set of embodiments, J is O.

In any of the foregoing embodiments, any group may be optionallysubstituted with an imaging moiety. In some embodiments, K, L, or M areindependently alkoxyalkyl, alkyloxy, aryl, or heteroaryl, optionallysubstituted with an imaging moiety. In one set of embodiments, K, L, orM are independently alkoxyalkyl, optionally substituted with an imagingmoiety.

In one set of embodiments, M is alkoxyalkyl, optionally substituted withan imaging moiety.

In some embodiments, the contrast agent is selected from the followinggroup:

In any of the foregoing aspects and embodiments, an alkyl group may beC₁₋₂₀ alkyl, C₁₋₁₀ alkyl, or C₁₋₆ alkyl, optionally substituted. In someembodiments, the alkyl group is C₁₋₆ alkyl, optionally substituted. Insome embodiments, the alkyl group is C₁₋₆ alkyl, optionally substitutedwith an imaging moiety.

In any of the forgoing aspects and embodiments, the contrast agent maybe provided in the presence of a pharmaceutically acceptable salt, asdisclosed herein.

In any of the forgoing aspects and embodiments, the contrast agent maybe provided in the presence of a counterion, or, in the absence of acounterion (e.g., as a free base).

In some embodiments, the present invention provides methods forsynthesizing any of the foregoing contrast agents according to themethods described herein. In some embodiments, the method may comprisereacting a compound with an imaging moiety precursor to form a contrastagent. In another embodiment, the method may comprise reacting anintermediate molecule to produce a contrast agent of the invention. Insome embodiments, the method may further comprise isolating and/orpurifying the intermediate molecule and/or contrast agent. The methodmay also comprise characterization of the intermediate molecule and/orcontrast agent.

In some embodiments, the present invention also provides methods formedical imaging; intravenous use in imaging; imaging at least a portionof the brain, central nervous system, or a cancer of a subject; infusionor injection; delivering an imaging agent to the brain or a tumor;imaging perfusion in a body region or structure (e.g., brain, CNS,tumor); determining the level of mitochondria and/or mitochondrialdensity in a subject or portion of a subject; diagnosing a disease in asubject, including diagnosing the onset, progression, and/or regressionof a disease; determining the stage of a disease in a subject; passing acontrast agent of the invention through the blood brain barrier of asubject; monitoring the accumulation of a contrast agent of theinvention in the brain of a subject; or treating a tumor, such as asolid tumor. In some embodiments, methods of the invention can be usedto assess efficacy of a treatment, for example, the brain, CNS, or acancer can be visualized using contrast agents of the invention before,during, and/or after treatment of a condition affecting the brain, CNS,or cancer of a subject. The method may comprise administering a contrastagent as described herein to a subject. In some embodiments, the methodcomprises passing a contrast agent of the invention through the bloodbrain barrier of a subject. In some embodiments, the method comprisesmonitoring the accumulation of a contrast agent of the invention in thebrain of a subject. All features disclosed in the specification may beused in combination with such methods.

In some embodiments, the present invention provides pharmaceuticalcompositions for medical imaging; intravenous use in imaging; imaging atleast a portion of the brain, central nervous system, or a cancer of asubject; infusion or injection; delivering an imaging agent to the brainor a tumor; imaging perfusion in a body region or structure (e.g.,brain, CNS, tumor); determining the level of mitochondria and/ormitochondrial density in a subject or portion of a subject; diagnosing adisease in a subject, including diagnosing the onset, progression,and/or regression of a disease; determining the stage of a disease in asubject; passing a contrast agent of the invention through the bloodbrain barrier of a subject; monitoring the accumulation of a contrastagent of the invention in the brain of a subject; or treating a tumor,such as a solid tumor. In some embodiments, the pharmaceuticalcomposition comprises a contrast agents as described herein, and one ormore pharmaceutically acceptable carriers, additives, and/or diluents.All features disclosed in the specification may be used in combinationwith such pharmaceutical compositions.

In some embodiments, the present invention relates to the use of any ofthe contrast agents described herein in the preparation of a medicamentfor medical imaging; intravenous use in imaging; imaging at least aportion of the brain, central nervous system, or a cancer of a subject;infusion or injection; delivering an imaging agent to the brain or atumor; imaging perfusion in a body region or structure (e.g., brain,CNS, tumor); determining the level of mitochondria and/or mitochondrialdensity in a subject or portion of a subject; diagnosing a disease in asubject, including diagnosing the onset, progression, and/or regressionof a disease; determining the stage of a disease in a subject; passing acontrast agent of the invention through the blood brain barrier of asubject; monitoring the accumulation of a contrast agent of theinvention in the brain of a subject; or treating a tumor, such as asolid tumor. Any of the uses described herein may comprise the use of acontrast agent of the present invention. All features disclosed in thespecification may be used in combination with such uses. In someembodiments, the present invention provides methods of treating apatient. The method may comprise the steps of administering to thepatient a contrast agent as in any foregoing embodiments; and acquiringan image of a site of concentration of the contrast agent in the patientby a diagnostic imaging technique.

The present invention also provides method for acquiring an image, orconstructing an image, of at least a portion of the brain, centralnervous system, or a cancer of a subject.

Any of the foregoing aspects and embodiments may comprise contacting atleast a portion of the brain, central nervous system, or a cancer of asubject with a contrast agent of the invention. In certain embodiments,the contacting may occur via administration of the contrast agent to thesubject. In one set of embodiments, the contacting may occur viaintravenous administration of the contrast agent to the subject.

In any of the foregoing aspects and embodiments, the disease may be aCNS disorder or condition, as described herein.

In any of the foregoing aspect and embodiments, the subject can beotherwise free of indications for perfusion imaging, such as myocardialperfusion imaging, for example.

Other aspects of the invention may include suitable combinations ofembodiments and aspects disclosed herein.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows representative images of the (a) transverse, (b) coronal,and (c) sagittal planes of a nonhuman primate brain, with2-tert-butyl-4-chloro-5-[4-(2-[¹⁸F]fluoro-ethoxymethyl)-benzyloxy]-2H-pyridazin-3-onein a normal NHP, where the whiter portions indicate localization of thecontrast agent.

FIG. 2A shows representative images of the transverse (left image) andsagittal (right image) sections of a rat brain imaged using2-tert-Butyl-4-chloro-5-[4-(2-(¹⁸F)fluoroethoxymethyl)-benzyloxy]-2H-pyridazin-3-one(Agent 2), where the whiter portions indicate localization of thecontrast agent.

FIG. 2B shows representative images of the transverse (left image) andsagittal (right image) sections of a rat brain imaged using2-tert-Butyl-4-chloro-5-[4-(3-(¹⁸F)fluoropropoxy)-benzyloxy]-2H-pyridazin-3-one(Agent 3), where the whiter portions indicate localization of thecontrast agent.

FIG. 3A shows representative tomographic images of the transverse (leftimage) and sagittal (right image) sections of a NHP brain imaged usingAgent 2, where the whiter portions indicate localization of the contrastagent.

FIG. 3B shows representative tomographic images of the transverse (leftimage) and sagittal sections (right image) of a NHP brain imaged using2-tert-butyl-4-chloro-5-[4-(4-[¹⁸F]fluoro-butyl)-benzyloxy]-2H-pyridazin-3-one(Agent 1), where the whiter portions indicate localization of thecontrast agent.

FIG. 4 shows representative transverse (left image) and coronal (rightimage) images of a c-neu ONCO mouse imaged with Agent 2, where thewhiter portions indicate localization of the contrast agent.

DETAILED DESCRIPTION

The present invention generally relates to methods for using contrastagents in imaging including perfusion imaging. In some embodiments,methods of the invention may be useful in imaging a location within asubject (e.g., mammal), including the brain, central nervous system,cancer, or portions thereof. Some embodiments of the invention mayprovide contrast agents, and related methods, that are selective forhigh energy demand tissues within a subject, in addition to a broaduptake mechanism. In some cases, contrast agents and methods describedherein advantageously exhibit high avidity for an intracellular targetwith a relatively low off rate, which may be useful in targetingprocesses associated with mitochondria.

Imaging Moieties

Examples of nuclear medicine contrast agents suitable for use in thepresent invention include, but are not limited to, ¹¹C, ¹³N, ¹⁸F, ¹²³I,and ¹²⁵I. In some cases, ¹¹C-Palmitate may be used to probe fatty acidoxidation and ¹¹C-acetate may be used to assess oxidative metabolism inthe myocardium (Circulation 1987, 76, 687-696). Agents based on ¹⁸F may,in some cases, be useful as imaging agents for hypoxia and cancer (Drugsof the Future 2002, 27, 655-667). In one set of embodiments, the imagingmoiety employed in contrast agents of the present invention is ¹⁸F. Insome embodiments, imaging moieties of the present invention may compriseone or more X-ray absorbing or “heavy” atoms having an atomic number of20 or greater. In some cases, the contrast agent may further comprise anoptional linking moiety, L, positioned between the parent molecularmoiety and one or more X-ray absorbing atoms. A non-limiting example ofa heavy atom used as X-ray contrast agents is iodine.

Some embodiments of the invention may be useful in imaging a cancerpresent within a subject. Many malignant cancers may be characterized byrapid undifferentiated cell growth. The energy to facilitate this growthis high, but therapeutic interruption of energy consumption may be fatalto the subject. Some embodiments of the invention may provide theability to image such energy consumption on a tracer level to provide atomography of high-energy demand tissues. Additionally, methods of theinvention allow for the imaging of primary tumors as well as metastaticneoplasia.

In some cases, methods for imaging central nervous system tissue, whichconsumes a disproportionate amount of energy, are provided. Theblood-brain barrier (BBB) is a physical entity that can prevent theindiscriminate passage of agents into the brain. Current agents that canimage mitochondrial density are lipophilic monocations, and aretypically excluded by the BBB from CNS uptake. In some cases, methodsdescribed herein provide agents that are capable of selectively imagingbrain tissue and crossing the blood brain barrier. Such methods may beuseful in imaging the topography and blood flow to the brain, as well asperfusion imaging in the brain.

Generally, the contrast agents described herein are capable of imagingand mapping mitochondrial density and function in tissues. Mitochondrialfunction has been indicated as causative or correlative in Alzheimer'Disease (AD; Wang, et al. Free Radical Biology and Medicine, 2007, 43,1569-1573, incorporated herein by reference in its entirety),Parkinson's Disease (Higgin and Greenamyre, Journal of Neuroscience,1996, 16(12), 3807-3816, incorporated herein by reference in itsentirety), as well as neuronal dysfunction and temporal lobe epilepsy(Kann and Kovacs, Am. J. Physiol. Cell Physiol. 2007, 292, C641-C657,incorporated herein by reference in its entirety). Agents such as thosedescribed herein can be used for the imaging of disease diagnosis,including, but not limited to, onset, progression, regression, andstaging.

In some embodiments, the contrast agent comprises an imaging moiety anda compound bound to the imaging moiety. The imaging agent may be boundto the compound via a bond, such as a covalent bond, an ionic bond, ahydrogen bond, a dative bond (e.g. complexation or chelation betweenmetal ions and monodentate or multidentate ligands), or the like. Inthis non-limiting example, the imaging agent may be a ¹⁸F atomcovalently bound to a compound. The compound can be selected from, forexample, pyridaben, fenazaquin, a pyridaben analog, a pyridimifenanalog, a tebufenpyrad analog, and an fenazaquin analog.

Methods of Synthesizing Contrast Agents

Typically, contrast agents described herein may be synthesized byreacting at least a first component and a second component, such that abond is formed therebetween. For example, ¹⁸F labeled compounds may besynthesized by reacting two components via S_(n)2 displacement of anappropriate leaving group associated with at least one component.Examples of such leaving groups include sulfonic acid esters such astoluenesulfonate (tosylate, TsO—), methanesulfonate (mesylate, MsO—), ortrifluoromethanesulfonate (triflate, TfO—). The leaving group may alsobe a halide, a phosphineoxide (via Mitsunobu reaction), or an internalleaving group (such as an epoxide or cyclic sulfate). In someembodiments, such compounds can be synthesized from highly activated,dry K¹⁸F, that is made more reactive by the addition of potassiumsequestering cryptands such as krytofix[2.2.2]. Purification isgenerally performed via salt removal by reverse-phase chromatography(SepPak™).

Representative methods of making the contrast agents are described inthe following examples. The foregoing chemical transformations may beconducted using techniques which would be readily apparent to one ofordinary skill in the art, in combination with the teachings describedherein. In some cases, methods of synthesizing the contrast agents mayinclude the use of one or more reaction solvents. Representativereaction solvents include, for example, DMF, NMP, DMSO, THF, ethylacetate, dichloromethane, and chloroform. The reaction solution may bekept neutral or basic by the addition of an amine such as triethylamineor DIEA. In some cases, the chemical transformations (e.g., reactions)may be carried out at ambient temperatures and protected from oxygen andwater with a nitrogen, argon or helium atmosphere.

In some embodiments, temporary protecting groups may be used to preventother reactive functionality, such as amines, thiols, alcohols, phenols,and carboxylic acids, from participating or interfering in the reaction.Representative amine protecting groups include, for example,tert-butoxycarbonyl and trityl (removed under mild acidic conditions),Fmoc (removed by the use of secondary amines such as piperidine), andbenzyloxycarbonyl (removed by strong acid or by catalytichydrogenolysis). The trityl group may also used for the protection ofthiols, phenols, and alcohols. In certain embodiments the carboxylicacid protecting groups include, for example, tert-butyl ester (removedby mild acid), benzyl ester (usually removed by catalytichydrogenolysis), and alkyl esters such as methyl or ethyl (usuallyremoved by mild base). All protecting groups may be removed at theconclusion of synthesis using the conditions described above for theindividual protecting groups, and the final product may be purified bytechniques which would be readily apparent to one of ordinary skill inthe art, in combination with the teachings described herein.

Use of Contrast Agents

The contrast agents of the present invention may be used in methods ofimaging, including methods of imaging in a subject. For example, themethod may comprise administering the contrast agent to the subject byinjection (e.g., intravenous injection), infusion, or any other knownmethod, and imaging the area of the subject wherein an event of interestis located.

The useful dosage to be administered and the particular mode ofadministration will vary depending upon such factors as age, weight, andparticular region to be imaged, as well as the particular contrast agentused, the diagnostic use contemplated, and the form of the formulation,for example, suspension, emulsion, microsphere, liposome, or the like,as will be readily apparent to those of ordinary skill in the art.

Typically, dosage is administered at lower levels and increased untilthe desirable diagnostic effect (e.g., production of an image) isachieved. In one embodiment, the above-described contrast agents may beadministered by intravenous injection, usually in saline solution, at adose of about 0.1 to about 100 mCi per 70 kg body weight (and allcombinations and subcombinations of dosage ranges and specific dosagestherein), or, in some embodiments, at a dose of about 0.5 to about 50mCi. Imaging is performed using techniques well known to the ordinarilyskilled artisan.

In some cases, for use as nuclear medicine contrast agents, thecompositions of the present invention, dosages, administered byintravenous injection, may be in the range from about 0.5 μmol/kg toabout 1.5 mmol/kg (and all combinations and subcombinations of dosageranges and specific dosages therein), and, in some embodiments, about0.8 μmol/kg to about 1.2 mmol/kg.

Another aspect of the present invention provides diagnostic kits for thepreparation of diagnostic agents for determining (e.g., detecting),imaging, and/or monitoring at least a portion of the brain, centralnervous system, or cancer. Diagnostic kits of the present invention maycomprise one or more vials containing a sterile, non-pyrogenic,formulation comprising a predetermined amount of a reagent (e.g.,contrast agent precursor) of the present invention, and optionally othercomponents such as chelating agents, solvents, buffers, neutralizationaids, lyophilization aids, stabilization aids, solubilization aids andbacteriostats, as described more fully below.

Some non-limiting examples of buffers useful in the preparation ofcontrast agents and kits include, for example, phosphate, citrate,sulfosalicylate, and acetate buffers. A more complete list can be foundin the United States Pharmacopoeia.

Some non-limiting examples of lyophilization aids useful in thepreparation of contrast agents and kits include, for example, mannitol,lactose, sorbitol, dextran, FICOLL® polymer, and polyvinylpyrrolidine(PVP).

Some non-limiting examples of stabilization aids useful in thepreparation of contrast agents and kits include, for example, ethanol,ascorbic acid, ethanol, cysteine, monothioglycerol, sodium bisulfite,sodium metabisulfite, gentisic acid, and inositol.

Some non-limiting examples of solubilization aids useful in thepreparation of contrast agents and kits include, for example, ethanol,glycerin, polyethylene glycol, propylene glycol, polyoxyethylenesorbitan monooleate, sorbitan monoloeate, polysorbates,poly(oxyethylene)-poly(oxypropylene)-poly(oxyethylene) block copolymers(“Pluronics®”) and lecithin.

Some non-limiting examples of bacteriostats useful in the preparation ofcontrast agents and kits include, for example, benzyl alcohol,benzalkonium chloride, chlorobutanol, and methyl, propyl, or butylparaben.

A component in a diagnostic kit of the invention can also serve morethan one function. For example, a solubilization aid may serve as astabilizer.

Many geometric isomers of olefins, C═N double bonds, and the like can bepresent in the compounds described herein, and all such stable isomersare contemplated in the present invention.

For the sake of simplicity, connection points (“-”) are not depicted.When an atom or compound is described to define a variable, it isunderstood that it is intended to replace the variable in a manner tosatisfy the valency of the atom or compound. For example, if a variable“A” was identified as “C(R⁸⁰)═C(R⁸⁰),” both carbon atoms would form apart of the chain in order to satisfy their respective valences.

When any variable occurs more than one time in any substituent or in anyformula, its definition in each occurrence is independent of itsdefinition at every other occurrence. Thus, for example, if a group, orplurality of groups, is shown to be substituted with 0-2 R⁸⁰, then saidgroup(s) may optionally be substituted with up to two R⁸⁰, and R⁸⁰ ateach occurrence in each group is selected independently from the definedlist of possible R⁸⁰. Also, by way of example, for the group —N(R⁸¹)₂,each of the two R⁸¹ substituents on N is independently selected from thedefined list of possible R⁸¹. Combinations of substituents and/orvariables are permissible only if such combinations result in stablecompounds. When a bond to a substituent is shown to cross the bondconnecting two atoms in a ring, then such substituent may be bonded toany atom on the ring.

Imaging Methods for Detecting Cancer and CNS Disorders and Conditions

Imaging methods of the invention can be used to diagnose and assesscancer and CNS disorders or conditions based on the determination oflevels and/or density of mitochondria in tissues, tissue regions, andsubjects through in vivo imaging. Determination of levels ormitochondria and/or mitochondrial density in tissues in a subjectpermits the diagnosis and assessment of disorders associated withaltered levels of mitochondria or mitochondrial density. Differences inlevels of mitochondria and/or mitochondrial density in tissues of asubject compared to levels of mitochondrial and/or mitochondrial densityin normal tissues (e.g. non-diseased) tissues can be used to diagnose orto aid in the diagnosis in the subject of disorders or conditions thatexhibit (e.g., are associated with) altered levels of mitochondriaand/or mitochondrial density. Particular types of disorders andconditions that can be assessed using imaging methods of the inventioninclude cancer and CNS disorders and conditions. Imaging methods of theinvention may be used in diagnostic methods alone or in conjunction withother diagnostic methods known in the art. One aspect of the presentinvention relates to the use of contrast agent comprising an imagingmoiety and a compound selected from pyridaben, fenazaquin, a pyridabenanalog, a pyridimifen analog, a tebufenpyrad analog, or a fenazaquinanalog for detecting mitochondrial levels in a subject. This methodinvolves administering to a subject a contrast agent that localizes inmitochondria, thus permitting detection in the subject of regions ortissues with altered or abnormal levels of mitochondria.

Methods of the invention can be used to assess or screen patients fordiseases associated with the presence of increased or decreased levelsof mitochondrial density in tissues. As used herein, the term“increased” means higher, for example higher versus a control level. Asused herein, the term “decreased” means lower, for example decreasedversus a control level. Methods of the invention may be used to identifythe status of disorders associated with abnormal levels of mitochondriain tissues or regions. The amount of mitochondria in a tissue or region,as compared to a control, can be used to determine the presence orabsence of a particular CNS disorder or cancer. Methods of the inventioncan be used to obtain useful prognostic information by providing anindicator of a CNS disorder or cancer in a subject, which can be used toselect a therapy for the subject.

Imaging methods of the invention can be used to detect levels ofmitochondria and/or mitochondrial density in subjects already diagnosedas having cancer or a CNS disorder or condition. In other instances,methods of the invention can be used to obtain measurements that providea diagnosis or aid in providing a diagnosis of a cancer or a CNSdisorder or condition. In some instances, a subject may be already beundergoing drug therapy for cancer or for a CNS disorder or condition,while in other instances a subject may be without present cancer therapyor therapy for a CNS disorder or condition. In some embodiments, themethod can be used to assess efficacy of a treatment. For example, thebrain, CNS, or a cancer can be visualized using contrast agents of theinvention before, during, and/or after treatment of a conditionaffecting the brain, CNS, or cancer of a subject.

According to the present invention, some subjects may be free ofsymptoms otherwise calling for treatment with a particular therapy, andimaging methods of the invention may identify the subject as needingtreatment. This means that absent the use of the imaging methods of theinvention to assess levels of mitochondria and/or mitochondrial density,the subject would not according to convention as of the date of thefiling of the present application have symptoms calling for treatmentwith a particular therapy. As a result of measuring the level ofmitochondria and/or mitochondrial density of tissues or body regions ofthe subject using methods of the invention, the subject becomes acandidate for treatment with a particular therapy. Thus, for example, asubject determined using imaging methods of the invention, to have anabove-normal level of mitochondria and/or mitochondrial density in atissue or body region may be determined to have cancer and these resultsmay be used to selected or aid in the selection of a treatment for thecancer.

As will be understood by those of ordinary skill in the art, imagingusing methods of the invention may include full body imaging of asubject, or imaging of a specific body region or tissue of interest. Forexample, if a subject is known or suspected of having a solid tumor inthe lung, methods of the invention may be used to image the tumor andlung. In some embodiments, imaging may be limited to the CNS and/or to aspecific region of the CNS. For example, in a subject with temporal lobeepilepsy, the temporal lobes may be imaged using methods of theinvention and for a subject for whom stroke or cerebral infarction issuspected or confirmed, imaging may include imaging of the entire brain.

In some aspects of the invention, imaging methods may include imaging ofa specific tissue, region, or structure (e.g., a tumor) and in someaspects may include imaging of perfusion of a body region or structure.For example, methods of the invention may be used to image a tumor orcancer in a subject, and may also be used to image perfusion of thebrain, or part of the brain, e.g., one or more brain structures.Perfusion of the brain will be understood by those of ordinary skill inthe art to reflect the blood flow through the brain. Perfusion of thebrain using methods of the invention may be useful to image regions ofdamage to the brain or regions of recovery of a previously damagedbrain. Non-limiting examples of the use of perfusion methods of theinvention include its use to image brain regions with reduced orobstructed blood flow resulting from an occlusion of blood vessels inthe brain and also include its use to image brain regions with excessiveblood flow, for example, resulting from a hemorrhagic event.

Some aspects of the invention include methods of administering to asubject an amount of a contrast agent effective to image a cancer in thesubject. Some aspects of the invention include methods of administeringto a subject an amount of a contrast agent effective to image a specificCNS region in the subject. Contrast agents of the invention, whenadministered to a subject, preferentially localize to mitochondria. Thelocalization of contrast agents to mitochondria permits determination ofrelative levels of mitochondria in tissues and regions in the subject.An increased amount of contrast agent of the invention localizes totissues and/or regions with higher levels of mitochondria and/or highermitochondrial density versus the amount of contrast agent that localizesin tissues or regions having a lower level of mitochondria and/or lowermitochondrial density in the tissue or region. The level or intensity ofan imaging signal localized to a tissue or body region of a subjectfollowing administration of a contrast agent in a method of theinvention, indicates the level of mitochondria and/or mitochondrialdensity in that tissue or body region. Similarly, a decreased amount ofcontrast agent of the invention localizes to tissues and/or regions withlower levels of mitochondria or mitochondrial density versus the amountof contrast agent that localizes to tissues or regions having a higherlevel of mitochondria and/or mitochondrial density. The level orintensity of an imaging signal localized to a tissue or body region of asubject following administration of a contrast agent in a method of theinvention, indicates the level of mitochondria and/or mitochondrialdensity in that tissue or body region. This ability to quantify theuptake of the agent into tissue of interest is inherent in the physicsof PET, which allows for relatively precise and accurate calculations ofuptake into tissues compared to the injected dose of imaging agent.Comparison of this uptake versus levels that are expected from normaltissues allows for assessment and diagnosis of the subject.

Information on mitochondria levels in tissues or body regions that isobtained using imaging methods of the invention may be used fordiagnosis of or to aid in the diagnosis of CNS disorders or conditions.Such information may also be used for diagnosis of or to aid in thediagnosis of cancer in a subject. In disorders characterized byincreased levels or density of mitochondria in tissues compared tohealthy tissues, an increase in imaging intensity in the tissues whenusing an imaging method of the invention may indicate the presence ofthe disorder. Similarly, in disorders characterized by decreased levelsor density of mitochondria in tissues compared to healthy tissues, adecrease in imaging intensity in the tissues when using an imagingmethod of the invention may indicate the presence of the disorder. Thoseof ordinary skill in the art will recognize that disorders characterizedby increased mitochondria density and disorders characterized bydecreased mitochondrial density can both be assessed using methods ofthe invention.

Imaging methods of the invention may be used to assess cancer or a CNSdisorder or condition and to select an appropriate treatment for asubject. In addition, imaging methods set forth herein are also usefulto monitor changes in a subject with respect to cancer or a CNS disorderor condition over time; for example, to assess the onset, progression,or regression of a cancer or a CNS disorder or condition in a subjectover a period of time. The mitochondrial level in a tissue of a subjectwith a CNS disorder or a cancer may be determined using imaging methodsof the invention at one, two, three, four, or more separate times. Thelevel of mitochondria in a specific CNS region or cancer in the subjectat the different times may be compared and changes in the mitochondriallevels over time may be used to assess the status and stage of thecancer or CNS disorder or condition in the subject and/or the effect ofa treatment strategy on the cancer or CNS disorder or condition in thesubject. Imaging methods of the invention can also be used to evaluate atreatment for a cancer or a CNS disorder or condition in a subject. Anincrease or decrease in the level of mitochondria or mitochondrialdensity in a tissue resulting from a treatment may be used to evaluatethe efficacy of the treatment.

In some aspects of the invention, changes in a cancer or CNS disorder ora condition in a subject resulting from treatment of a CNS disorder orcancer in a subject can be determined using methods of the invention toprovide a determination of the efficacy of a treatment or therapeuticprotocol in the subject. For example, a level of mitochondria and/ormitochondrial density in a region of the CNS can be obtained usingimaging methods of the invention prior to the start of a therapeuticregimen (either prophylactic or as a treatment of the CNS disorder orcondition); during the treatment regimen; and/or after a treatmentregimen, thus providing information on changes in the status of the CNSdisorder or condition over the course of the treatment. Similarly,determinations made using imaging methods of the invention at two ormore time points before, during, and/or after treatment for a cancer maybe useful to assess the efficacy of the therapeutic regimen for thecancer.

It will be understood that a therapeutic regimen may be eitherprophylactic or a treatment of a cancer or CNS disorder or condition ina subject. Thus, methods of the invention may be used to monitor asubject's response to prophylactic therapy and/or treatment provided toa patient having or at risk of having a CNS disorder or a cancer.

Methods of the invention may also be used in a variety of assays basedupon detecting levels of mitochondria in tissues or regions.Non-limiting examples of assays include (1) evaluating a treatment of aCNS disorder or cancer in a subject; (2) selecting a treatment for a CNSdisorder or a cancer based at least in part on the imaging ofmitochondrial levels in a tissue or body region of the subject; and (3)determining the status of a CNS disorder or cancer in the subject. Thus,subjects can be characterized, treatment regimens can be monitored,treatments can be selected and diseases status can be better understoodusing methods of the present invention.

Methods described herein include the use of contrast agents of theinvention and may involve determining levels of mitochondria ormitochondria density in tissues and/or regions of a subject. Levels ofmitochondria and mitochondrial density in a tissue or region in asubject can be determined in a number of ways when carrying out thevarious methods of the invention. In one particularly importantmeasurement, a level of mitochondria and/or mitochondrial density ismeasured in relation to a control level of mitochondria and/ormitochondrial density in a tissue or region of a subject. One possiblemeasurement of the level of mitochondria and/or mitochondrial density isa measurement of absolute levels of mitochondria and/or mitochondrialdensity. This could be expressed, for example, in mitochondria and/ormitochondrial density unit of cells or tissue. Another measurement ofthe level of mitochondria and/or mitochondrial density is a measurementof the change in the level of mitochondria and/or mitochondrial densityover time. This may be expressed in an absolute amount or may beexpressed in terms of a percentage increase or decrease over time.

Controls

Importantly, levels of mitochondria and/or mitochondrial density can bedetermined using imaging methods of the invention and are advantageouslycompared to controls according to the invention. A control may be apredetermined value, which can take a variety of forms. It can be asingle cut-off value, such as a median or mean. It can be establishedbased upon comparative groups, such as in groups having normal levels ofmitochondria and/or mitochondrial density and groups having abnormallevels of mitochondria and/or mitochondrial density. Another example ofcomparative groups may be groups having cancer or cancer symptoms andgroups without cancer or cancer symptoms or groups having symptoms of aCNS disorder or condition and groups not having symptoms of a CNSdisorder or condition. Another comparative group may be a group with afamily history of cancer or a CNS disorder or condition and a groupwithout such a family history. A predetermined value can be arranged,for example, where a tested population is divided equally (or unequally)into groups, such as a low-risk group, a medium-risk group and ahigh-risk group or into quadrants or quintiles, the lowest quadrant orquintile being individuals with the lowest risk (e.g. of cancer or of aCNS disorder or condition) and lowest levels of mitochondria and/ormitochondrial density and the highest quadrant or quintile beingindividuals with the highest risk (e.g. of cancer or of a CNS disorderor condition) and highest levels of mitochondria and/or mitochondrialdensity. It will be understood by those of ordinary skill in the artthat some CNS disorders or conditions are associated with a higher levelof mitochondria and/or mitochondrial density and other CNS disorders orconditions are associated with a lower level of mitochondria and/ormitochondrial density. One of ordinary skill in the art will be able toassign the population and risk groupings based on the specific CNSdisorder or condition of interest.

The predetermined value, of course, will depend upon the particularpopulation selected. For example, an apparently healthy population willhave a different ‘normal’ range than will a population that is known tohave a condition related to abnormal mitochondria and/or mitochondrialdensity. Accordingly, the predetermined value selected may take intoaccount the category in which an individual or tissue falls. Appropriateranges and categories can be selected with no more than routineexperimentation by those of ordinary skill in the art. As used herein,“abnormal” means not normal as compared to a control. By abnormally highit is meant high relative to a selected control. By abnormally low it ismeant low relative to a selected control. Typically a control will bebased on apparently healthy tissue or individuals in an appropriate agebracket or apparently healthy tissues. It will be understood thatcontrols according to the invention may be, in addition to predeterminedvalues, subjects imaged under the substantially similar conditions withthe test subject. In some aspects of the invention, a control image fora subject may be a prior image from the same subject.

As mentioned above, it is also possible to use the imaging methods ofthe invention to characterize mitochondria and/or mitochondrial densitylevels by monitoring changes in the amount of mitochondria and/ormitochondrial density over time. For example, it is expected that insome disorders or conditions a decrease in mitochondria and/ormitochondrial density correlates with improvement of the disorder orcondition and in other disorders or conditions an increase inmitochondria and/or mitochondrial density correlates with improvement ofthe disorder or condition. Accordingly one can monitor levels ofmitochondria and/or mitochondrial density over time to determine ifthere is a change in the subject's disorder or condition status. Changesin levels of mitochondria and/or mitochondrial density greater than 0.1%may indicate an abnormality. Preferably, the change (in some disordersan increase and in other disorders a decrease) in mitochondria and/ormitochondrial density, which indicates an abnormality, is a changegreater than 0.2%, greater than 0.5%, greater than 1.0%, 2.0%, 3.0%,4.0%, 5.0%, 7.0%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, or more. Changes inthe amount of mitochondria and/or mitochondrial density over time mayindicate a change in the status of the disorder or condition in thesubject.

Imaging methods of the invention may also be used in diagnostic methodsto determine the effectiveness of treatments for cancer or a CNSdisorder or condition. “Evaluation of treatment” as used herein, meansthe comparison of a subject's levels of mitochondria and/ormitochondrial density measured in a subject at different imaging times,preferably at least one day apart. In some embodiments, the time atwhich the subject is administered a contrast agent and imaged using amethod of the invention and is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 36, 48, 72, 96,120, or more hours (including all times between) after obtaining thefirst sample from the subject. In some embodiments, the time at whichthe subject is administered a contrast agent and imaged using a methodof the invention is at least 5, 10, 15, 20, 30, 50, 80, 100, 200, 500,1000, or more days after the previous image (including all timesbetween).

Imaging methods of the invention may be used to allow the comparison oflevels of mitochondria and/or mitochondrial density in two or moresamples, taken at different times, which may be used to detect thestatus of a cancer or a CNS disorder or condition in a subject andallows evaluation of a cancer treatment or treatment of the CNS disorderor condition. The comparison of a subject's levels of mitochondriaand/or mitochondrial density determined using methods of the inventionat different times and/or on different days provides a measure of thestatus of the cancer or CNS disorder or condition that can be used todetermine the effectiveness of any treatment of the cancer or CNSdisorder or condition in a subject.

Kits

In some aspects of the invention, kits are provided. Kits containingcontrast and imaging agents of the invention can be prepared for in vivodiagnosis, prognosis and/or monitoring the level of mitochondria and/ormitochondrial density in tissues, and/or subjects using methodsdescribed herein. Components of the kits can be packaged as pure solidor liquids, in aqueous medium, in organic solutions or in lyophilizedform. When the contrast agent of the invention are used in the kits inthe form of conjugates in which an imaging moiety is attached, such as aradioactive element, the components of such conjugates can be suppliedeither in fully conjugated form, in the form of intermediates or asseparate moieties to be conjugated by the user or the kit.

A kit may comprise a carrier being compartmentalized to receive in closeconfinement therein one or more container means or series of containermeans such as test tubes, vials, flasks, bottles, syringes, or the like.A first of said container means or series of container means may containa contrast agent precursor. A second container may contain adjuvents forfacilitating the conversion of the contrast agent precursor to thecontrast agent and its subsequent manipulation into a suitable dosageform.

A kit of the invention may also include instructions. Instructionstypically will be in written form and will provide guidance forcarrying-out the synthesis of the imaging agent by the kit and forformulating a suitable dose from the results of said synthesis.

DEFINITIONS

For convenience, certain terms employed in the specification, examples,and appended claims are listed here.

The number of carbon atoms in any particular group is denoted before therecitation of the group. For example, the term “C₆-C₁₀aryl” denotes anaryl group containing from six to ten carbon atoms, and the term“C₆-C₁₀aryl-C₁-C₁₀alkyl,” refers to an aryl group of six to ten carbonatoms attached to the parent molecular moiety through an alkyl group ofone to ten carbon atoms.

The term “alkenyl,” as used herein, refers to a straight or branchedchain hydrocarbon containing at least one carbon-carbon double bond.

The term “alkoxy,” as used herein, refers to a C₁-C₆ alkyl groupattached to the parent molecular moiety through an oxygen atom.

The term “alkoxyalkyl,” as used herein, refers to a C₁-C₆ alkyl groupsubstituted with one, two, or three alkoxy groups.

The term “alkyl,” as used herein, refers to a group derived from astraight or branched chain saturated hydrocarbon.

The term “alkylaryl,” as used herein, refers to an alkyl group attachedto the parent molecular moiety through an aryl group.

The term “alkylene,” as used herein, refers to a divalent group derivedfrom a straight or branched chain saturated hydrocarbon.

The term “alkyloxy,” as used herein, refers to a C₁-C₆ alkyl groupattached to the parent molecular moiety through an oxygen atom.

The term “analog moiety,” as used herein, refers to the compounds of thepresent invention excluding the imaging moiety or moieties.

The term “aryl,” as used herein, refers to a phenyl group, or a bicyclicfused ring system wherein one or more of the rings is a phenyl group.Bicyclic fused ring systems consist of a phenyl group fused to amonocyclic cycloalkenyl group, a monocyclic cycloalkyl group, or anotherphenyl group. The aryl groups of the present invention can be attachedto the parent molecular moiety through any substitutable carbon atom inthe group. Representative examples of aryl groups include, but are notlimited to, anthracenyl, azulenyl, fluorenyl, indanyl, indenyl,naphthyl, phenyl, and tetrahydronaphthyl.

The term “arylalkyl,” as used herein, refers to an alkyl groupsubstituted with one, two, or three aryl groups.

The term “arylalkylene,” as used herein, refers to a divalent arylalkylgroup, where one point of attachment to the parent molecular moiety ison the aryl portion and the other is on the alkyl portion.

The term “arylene,” as used herein, refers to a divalent aryl group.

A “bacteriostat” is a component that inhibits the growth of bacteria ina formulation either during its storage before use of after a diagnostickit is used to synthesize a radiopharmaceutical.

The terms “brain” and “central nervous system” as used herein areintended to be interchangeable and are not to be construed as mutuallyexclusive.

The term “cancer” as used herein refers to neoplasia, oncologic growths,malignant tumors, benign tumors, metastases, or undifferentiatedcellular growths.

The term “contrast agent,” as used herein, refers to an agent used tohighlight specific areas so that organs, blood vessels, and/or tissuesare more visible using methods such as. By increasing the visibility ofthe surfaces being studied, the presence and extent of disease and/orinjury can be determined.

The term “cycloalkenyl,” as used herein, refers to a non-aromatic,partially unsaturated monocyclic, bicyclic, or tricyclic ring systemhaving three to fourteen carbon atoms and zero heteroatoms.Representative examples of cycloalkenyl groups include, but are notlimited to, cyclohexenyl, octahydronaphthalenyl, and norbornylenyl.

The term “cycloalkyl,” as used herein, refers to a saturated monocyclic,bicyclic, or tricyclic hydrocarbon ring system having three to fourteencarbon atoms and zero heteroatoms. Representative examples of cycloalkylgroups include, but are not limited to, cyclopropyl, cyclopentyl,bicyclo[3.1.1]heptyl, and adamantyl.

The term “C₃-C₁₀ cycloalkylene,” as used herein, refers to a divalentcycloalkyl group containing from three to ten carbon atoms.

The term “determining” or “determination,” as used herein, generallyrefers to the analysis of a species or signal (e.g., image), forexample, quantitatively or qualitatively, and/or the detection of thepresence or absence of the species or signals. “Determining” may alsorefer to the analysis of an interaction between two or more species orsignals, for example, quantitatively or qualitatively, and/or bydetecting the presence or absence of the interaction.

The term “diagnostic imaging,” as used herein, refers to a procedureused to detect a contrast agent.

A “diagnostic kit” or “kit” comprises a collection of components, termedthe formulation, in one or more vials which are used by the practicingend user in a clinical or pharmacy setting to synthesize diagnosticradiopharmaceuticals. In some embodiments, the kit may provide all therequisite components to synthesize and use the diagnostic pharmaceuticalexcept those that are commonly available to the practicing end user,such as water or saline for injection, a solution of the radionuclide,equipment for processing the kit during the synthesis and manipulationof the radiopharmaceutical, if required, equipment necessary foradministering the radiopharmaceutical to the subject such as syringes,shielding, imaging equipment, and the like. In some embodiments,contrast agents may be provided to the end user in their final form in aformulation contained typically in one vial or syringe, as either alyophilized solid or an aqueous solution.

The terms “halo” and “halogen,” as used herein, refer to F, Cl, Br, orI.

The term “haloalkyl,” as used herein, refers to a C₁-C₆ alkyl groupsubstituted by one, two, three, or four halogen atoms.

The term “heteroaryl,” as used herein, refers to an aromatic five- orsix-membered ring where at least one atom is selected from N, O, and S,and the remaining atoms are carbon. The term “heteroaryl” also includesbicyclic systems where a heteroaryl ring is fused to a four- tosix-membered aromatic or non-aromatic ring containing zero, one, or twoadditional heteroatoms selected from N, O, and S. The heteroaryl groupsare attached to the parent molecular moiety through any substitutablecarbon or nitrogen atom in the group. Representative examples ofheteroaryl groups include, but are not limited to, benzoxadiazolyl,benzoxazolyl, benzofuranyl, benzothienyl, furanyl, imidazolyl,indazolyl, indolyl, isoxazolyl, isoquinolinyl, isothiazolyl,naphthyridinyl, oxadiazolyl, oxazolyl, pyridinyl, pyridazinyl,pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, quinolinyl, thiazolyl,thienopyridinyl, thienyl, triazolyl, thiadiazolyl, and triazinyl.

The term “heterocyclyl,” as used herein, refers to a five-, six-, orseven-membered ring containing one, two, or three heteroatomsindependently selected from the group consisting of nitrogen, oxygen,and sulfur. The five-membered ring has zero to two double bonds and thesix- and seven-membered rings have zero to three double bonds. The term“heterocyclyl” also includes bicyclic groups in which the heterocyclylring is fused to a phenyl group, a monocyclic cycloalkenyl group, amonocyclic cycloalkyl group, or another monocyclic heterocyclyl group.The heterocyclyl groups of the present invention can be attached to theparent molecular moiety through a carbon atom or a nitrogen atom in thegroup. Examples of heterocyclyl groups include, but are not limited to,benzothienyl, furyl, imidazolyl, indolinyl, indolyl, isothiazolyl,isoxazolyl, morpholinyl, oxazolyl, piperazinyl, piperidinyl, pyrazolyl,pyridinyl, pyrrolidinyl, pyrrolopyridinyl, pyrrolyl, thiazolyl, thienyl,and thiomorpholinyl.

The term “heterocyclylalkyl,” as used herein, refers to an alkyl groupsubstituted with one, two, or three heterocyclyl groups.

The term “heterocyclylalkylene,” as used herein, refers to a divalentheterocyclylalkyl group, where one point of attachment to the parentmolecular moiety is on the heterocyclyl portion and the other is on thealkyl portion.

The term “heterocyclylene,” as used herein, refers to a divalentheterocyclyl group.

The term “hydroxy,” as used herein, refers to —OH.

The term “imaging moiety,” as used herein, refer to a portion orportions of a molecule that allow for the detection, imaging, and/ormonitoring of the presence and/or progression of a condition(s),pathological disorder(s), and/or disease(s).

The term “linking group,” as used herein, refers to a portion of amolecule that serves as a spacer between two other portions of themolecule. Linking groups may also serve other functions as describedherein. Examples of linking groups include linear, branched, or cyclicalkyl, aryl, ether, polyhydroxy, polyether, polyamine, heterocyclic,aromatic, hydrazide, peptide, peptoid, or other physiologicallycompatible covalent linkages or combinations thereof.

A “lyophilization aid” is a component that has favorable physicalproperties for lyophilization, such as the glass transition temperature,and is generally added to the formulation to improve the physicalproperties of the combination of all the components of the formulationfor lyophilization.

The term “oxo,” as used herein, refers to ═O.

Any of the contrast agents described herein may be optionallysubstituted with one or more of the following: alkyl, alkenyl,cycloalkyl, alkylaryl, alkylcarbonyl, aryl, arylalkyl, alkylarylalkyl,alkoxy, alkoxyalkyl, alkoxycarbonyl, heteroalkyl, heterocyclyl,heterocyclylalkyl, amino, thiol, —OH, phosphate, —CO₂H, ═O, halo,trifluoromethyl, nitro, cyano, ester, aldehyde, amide, keto, azide,sulfhydryl, imino, phosphonate, phosphinate, carbonyl, carboxyl, silyl,ether, alkylthio, sulfonyl, or sulfonamido, each of which may beoptionally substituted. In some embodiments, the contrast agent may besubstituted with an imaging agent.

The term “pyridaben” is given its ordinary meaning in the art and refersto a compound having the structure,

The term “pyridaben analog” refers to analogs of pyridaben, including,but not limited to, the contrast agents of Formula (II), as describedherein.

The term “fenazaquin” is given its ordinary meaning in the art andrefers to a compound having the structure,

The term “fenazaquin analog” refers to analogs of fenazaquin, including,but not limited to, the contrast agents of Formula (III), as describedherein.

As used herein, the phrase “pharmaceutically acceptable” refers to thosecompounds, materials, compositions, and/or dosage forms that are, withinthe scope of sound medical judgment, suitable for use in contact withthe tissues of human beings and animals without excessive toxicity,irritation, allergic response, or other problem or complication,commensurate with a reasonable benefit/risk ratio.

The term “pharmaceutically acceptable salt,” as used herein, representssalts or zwitterionic forms of the compounds of the present inventionwhich are water or oil-soluble or dispersible, which are, within thescope of sound medical judgment, suitable for use in contact with thetissues of subjects without excessive toxicity, irritation, allergicresponse, or other problem or complication commensurate with areasonable benefit/risk ratio, and are effective for their intended useThe salts can be prepared during the final isolation and purification ofthe compounds or separately by reacting a suitable nitrogen atom with asuitable acid. Representative acid addition salts include acetate,adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate,bisulfate, butyrate, camphorate, camphorsulfonate; digluconate,glycerophosphate, hemisulfate, heptanoate, hexanoate, formate, fumarate,hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate,lactate, maleate, mesitylenesulfonate, methanesulfonate,naphthalenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate,palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate,propionate, succinate, tartrate, trichloroacetate, trifluoroacetate,phosphate, glutamate, bicarbonate, para-toluenesulfonate, andundecanoate. Examples of acids which can be employed to formpharmaceutically acceptable addition salts include inorganic acids suchas hydrochloric, hydrobromic, sulfuric, and phosphoric, and organicacids such as oxalic, maleic, succinic, and citric.

As used herein, a “portion of a brain” refers to a particular region ofthe brain, location in the brain, or structure of the brain.

As used herein, a “portion of the CNS” refers to a particular region ofthe CNS, location in the CNS, or structure of the CNS.

As used herein, a “portion of a subject” refers to a particular regionof a subject, location in the subject, or structure of the subject. Forexample, a portion of a subject may be the brain of a subject.

The phrase “protecting group” as used herein refers to temporarysubstituents which protect a potentially reactive functional group fromundesired chemical transformations. Examples of such protecting groupsinclude esters of carboxylic acids, silyl ethers of alcohols, andacetals and ketals of aldehydes and ketones, respectively. The field ofprotecting group chemistry has been reviewed (Greene, T. W.; Wuts, P. G.M. Protective Groups in Organic Synthesis, 2^(nd) ed.; Wiley: New York,1991).

By “reagent” is meant a compound of this disclosure capable of directtransformation into a metallopharmaceutical of this disclosure. Reagentsmay be utilized directly for the preparation of themetallopharmaceuticals of this disclosure or may be a component in a kitof this disclosure.

As used herein, the term “react” or “reacting” refers to the formationof a bond between two or more components to produce a stable, isolablecompound. For example, a first component and a second component mayreact to form one reaction product (e.g., contrast agent) comprisingsubstantial portions of or the entirety of the first component and thesecond component joined by a covalent bond. That is, the term “reacting”does not refer to the interaction of solvents, catalysts, bases,ligands, or other materials which may serve to promote the occurrence ofthe reaction with the component(s).

A “stable, isolable compound” refers to isolated reaction products anddoes not refer to unstable intermediates or transition states.

A “stabilization aid” is a component that is typically added to themetallopharmaceutical or to the diagnostic kit either to stabilize themetallopharmaceutical or to prolong the shelf-life of the kit before itmust be used. Stabilization aids can be antioxidants, reducing agents orradical scavengers and can provide improved stability by reactingpreferentially with species that degrade other components or themetallopharmaceuticals.

By “stable compound” or “stable structure” is meant herein a compoundthat is sufficiently robust to survive isolation to a useful degree ofpurity from a reaction mixture, and formulation into an efficaciouspharmaceutical agent.

A “solubilization aid” is a component that improves the solubility ofone or more other components in the medium required for the formulation.

The term “thiol protecting group,” as used herein, refers to a groupintended to protect a thiol group against undesirable reactions duringsynthetic procedures. Any thiol protecting group known in the art may beused. Examples of thiol protecting groups include, but are not limitedto, the following: acetamidomethyl, benzamidomethyl, 1-ethoxyethyl,benzoyl, and triphenylmethyl.

As used herein, the term “subject” refers to a human or non-human mammalor animal. Non-human mammals include livestock animals, companionanimals, laboratory animals, and non-human primates. Non-human subjectsalso specifically include, without limitation, horses, cows, pigs,goats, dogs, cats, mice, rats, guinea pigs, gerbils, hamsters, mink, andrabbits. As used herein, the term “patient” refers to a subject who isunder the care of a physician or other health care worker, including,but not limited to, someone who has consulted with, received advice fromor received a prescription or other recommendation from a physician orother health care worker. A patient is typically a subject having or atrisk of having cancer or a CNS disorder or condition.

Some subjects to which the present invention can be applied are subjectswith CNS disorders or conditions or subjects with cancer. The terms“subject with cancer” or “subject with a CNS disorder or condition” asused herein, means an individual who, at the time the imaging, has beendiagnosed as having cancer or a CNS disorder or condition respectively.Methods of the invention may also be used to detect abnormal levels ordensity of mitochondria in tissues or regions in subjects that are notyet diagnosed with cancer or a CNS disorder or condition and thus areuseful for initial or confirmatory diagnosis of cancer or of a CNSdisorder or condition in a subject.

As used herein, the term “CNS disorder or condition” includes, but isnot limited to, epilepsy, aging, stress disorder, schizophrenia,Huntington's disease, Alzheimer's disease, Parkinson's disease, cerebralhypoxia, cerebral infarction and/or neural cell injury associated with astroke, Guillian Barre, arachnoiditis, brain abscess, CNS infection,cerebral palsy, corticobasal ganglionic degeneration (CBGD),Creutzfeldt-Jakob syndrome, Dandy-Walker syndrome, dementia,encephalitis, Herpes Simplex, encephalomyelitis, essential tremor,Friedreich Ataxia, Gerstmann-Straussler-Scheinker disease,hydrocephalus, Fatal Familial Insomnia, Kuru, Landau-Kleffner Syndrome,Lewy Body disease, Machado-Joseph disease, Meige Syndrome, meningitis(viral or bacterial), migraine disorders, movement disorders, MultipleSystem Atrophy, myelitis, Olivopontocerebellar atrophies, pantothenatekinase-associated neurodegeneration, poliomyelitis, postpoliomyelitissyndrome, prion diseases, pseudotumor cerebri, Shy-Drager syndrome,spinal cord diseases, Supranuclear Palsy, Syringomyelia, thalamicdiseases, tic disorders, Tourette syndrome, Uveomeningoencephaliticsyndrome.

Examples of categories of CNS disorders or conditions include, but arenot limited to lesions of either the central (including spinal cord,brain) or peripheral nervous systems such as: (1) ischemic lesions, inwhich a lack of oxygen in a portion of the nervous system results inneuronal injury or death, including cerebral infarction or ischemia, orspinal cord infarction or ischemia; (2) traumatic lesions, includinglesions caused by physical injury or associated with surgery, forexample, lesions which sever a portion of the nervous system, orcompression injuries; (3) malignant lesions, in which a portion of thenervous system is destroyed or injured by malignant tissue which iseither a nervous system associated malignancy or a malignancy derivedfrom non-nervous system tissue; (4) infectious lesions, in which aportion of the nervous system is destroyed or injured as a result ofinfection, for example, by an abscess or associated with infection byhuman immunodeficiency virus, herpes zoster, or herpes simplex virus orwith Lyme disease, tuberculosis, syphilis; (5) degenerative lesions, inwhich a portion of the nervous system is destroyed or injured as aresult of a degenerative process including but not limited todegeneration associated with Parkinson's disease, Alzheimer's disease,Huntington's chorea, or amyotrophic lateral sclerosis (ALS); (6) lesionsassociated with nutritional diseases, disorders, and/or conditions, inwhich a portion of the nervous system is destroyed or injured by anutritional disorder or disorder of metabolism including but not limitedto, vitamin B12 deficiency, folic acid deficiency, Wernicke disease,tobacco-alcohol amblyopia, Marchiafava-Bignami disease (primarydegeneration of the corpus callosum), and alcoholic cerebellardegeneration; (7) neurological lesions associated with systemic diseasesincluding, but not limited to, diabetes (diabetic neuropathy, Bell'spalsy), systemic lupus erythematosus, carcinoma, or sarcoidosis; (8)lesions caused by toxic substances including alcohol, lead, orparticular neurotoxins; and (9) demyelinated lesions in which a portionof the nervous system is destroyed or injured by a demyelinating diseaseincluding, but not limited to, multiple sclerosis, humanimmunodeficiency virus-associated myelopathy, transverse myelopathy orvarious etiologies, progressive multifocal leukoencephalopathy, andcentral pontine myelinolysis.

As used herein, the term “cancer” refers to an uncontrolled growth ofcells that may interfere with the normal functioning of the bodilyorgans and systems, and includes both primary and metastatic tumors.Primary tumors or cancers that migrate from their original location andseed vital organs can eventually lead to the death of the subjectthrough the functional deterioration of the affected organs. Ametastasis is a cancer cell or group of cancer cells, distinct from theprimary tumor location, resulting from the dissemination of cancer cellsfrom the primary tumor to other parts of the body. Metastases mayeventually result in death of a subject. Imaging methods of theinvention may also be used to assess the status of precancerousconditions, (e.g., conditions if left untreated are likely to lead tocancer in a subject)

As used herein, the term “cancer” includes, but is not limited to, thefollowing types of cancer: breast cancer (including carcinoma in situ),biliary tract cancer; bladder cancer; brain cancer includingglioblastomas and medulloblastomas; cervical cancer; choriocarcinoma;colon cancer; endometrial cancer; esophageal cancer; gastric cancer;hematological neoplasms including acute lymphocytic and myelogenousleukemia; T-cell acute lymphoblastic leukemia/lymphoma; hairy cellleukemia; chromic myelogenous leukemia, multiple myeloma;AIDS-associated leukemias and adult T-cell leukemia lymphoma;intraepithelial neoplasms including Bowen's disease and Paget's disease;liver cancer; lung cancer; lymphomas including Hodgkin's disease andlymphocytic lymphomas; mesothelioma, neuroblastomas; oral cancerincluding squamous cell carcinoma; ovarian cancer including thosearising from epithelial cells, stromal cells, germ cells and mesenchymalcells; pancreatic cancer; prostate cancer; rectal cancer; sarcomasincluding leiomyosarcoma, rhabdomyosarcoma, liposarcoma, fibrosarcoma,and osteosarcoma; skin cancer including melanoma, Merkel cell carcinoma,Kaposi's sarcoma, basal cell carcinoma, and squamous cell cancer;cancers of the head and neck, testicular cancer including germinaltumors such as seminoma, non-seminoma (teratomas, choriocarcinomas),stromal tumors, and germ cell tumors; thyroid cancer including thyroidadenocarcinoma and medullar carcinoma; and renal cancer includingadenocarcinoma and Wilms tumor. Non-limiting examples of precancerousconditions include dysplasia, premalignant lesions, adenomatous colonpolyp, and carcinoma in-situ such as Ductal carcinoma in-situ (DCIS),etc. Other cancers that can be imaged with methods of the invention willbe known to those of ordinary skill in the art.

EXAMPLES

The present invention will now be described in connection with certainembodiments which are not intended to limit its scope. On the contrary,the present invention covers all alternatives, modifications, andequivalents as can be included within the scope of the claims. Thus, thefollowing examples will illustrate one practice of the presentinvention, it being understood that the examples are for the purposes ofillustration of certain embodiments and are presented to provide what isbelieved to be the most useful and readily understood description of itsprocedures and conceptual aspects.

Example 1 Synthesis of Fenazaquin Analog Example 1A Synthesis of4-[4-(2-Hydroxyethyl)phenyl]-4-oxo-butyric acid methyl ester

To a dry 250 mL flask under a nitrogen atmosphere was added phenethylalcohol (2.50 g, 0.02 mol), anhydrous dichloromethane (150 mL), andmethyl-4-chloro-4-oxobutyrate (6.02 g, 0.04 mol). The contents of theflask were cooled to 0° C. with an ice bath. To the solution was addedaluminum chloride (25 g, 0.2 mol) in portions being careful to avoid aviolent exotherm. The resulting yellowish mixture was stirred for 3hours. At this point the reaction was quenched with ice water. Themixture was diluted with dichloromethane and transferred to a separatoryfunnel. The organic layer was washed with a saturated solution of sodiumbicarbonate, brine and then dried over magnesium sulfate. Filtration andconcentration of the filtrate under reduced pressure provided a crudeyellow oil. The oil was suspended in anhydrous methanol (100 mL) andsodium metal was added to the mixture until a pH of 9 was obtained. Themixture was stirred for 3 hours. The volume was reduced and then dilutedwith ethyl acetate. The solution was transferred to a separatory funneland washed with aqueous 0.05 N hydrochloric acid, brine and dried overmagnesium sulfate. The solution was concentrated under reduced pressureto give a crude yellow oil with a mass of 5.88 g. Column chromatography[silica gel; eluent hexanes-ethyl acetate (3:2)] provided the desiredproduct (2.69 g, 57%). ¹H (CDCl₃) δ(ppm): 2.65 (t, 2H); 2.81 (t, 2H);3.19 (t, 2H); 3.6 (s, 3H); 3.75 (t, 2H); 7.22 (d, 2H); 7.81 (d, 2H). ¹³C(CDCl₃) δ(ppm): 27.76, 33.03, 38.66, 51.52, 62.68, 127.97, 128.99,134.47, 144.78, 173.21, 197.64.

Example 1B Synthesis of 4-[4-(2-hydroxyethyl)phenyl]butyric acid methylester

A mixture of Example 1A (2.50 g, 11 mmol), 10% Pd/C (0.25 g, 0.23 mmolof Pd metal) in anhydrous methanol (25 mL) was first degassed to removeair (two vacuum/H₂ cycles) after which it was capped and a balloonfilled with H₂ was applied to it for 12 hours. After this time thereaction mixture was filtered through diatomaceous earth (Celite®) andthe filtrate was concentrated under reduced pressure to give 2.32 g ofcrude material. Column chromatography [silica gel; eluent hexanes-ethylacetate (2:1)] provided the desired product (0.92 g, 39%). ¹H (CDCl₃)δ(ppm): 1.91-1.96 (m, 2H); 2.32 (t, 2H); 2.62 (t, 2H); 2.83 (t, 2H);3.66 (s, 3H); 3.85 (t, 2H); 7.11-7.15 (m, 4H).

Example 1C Synthesis of 4-{4-[2-(quinazolin-4-yloxy)ethyl]phenyl}butyricacid methyl ester

A dry 50 mL flask was fitted with an addition funnel. To the flask wereadded 4-chloroquinazoline (592 mg, 3.6 mmol), anhydrous tetrahydrofuran(10 mL), and 60 wt % sodium hydride (187 mg, 4.7 mmol). A solution ofExample 1B (800 mg, 3.6 mmol) in anhydrous tetrahydrofuran (10 mL) wasadded dropwise using the addition funnel. The reaction was stirred for3.5 hours. The reaction was diluted with ethyl acetate and quenched bythe addition of aqueous 0.1 N hydrochloric acid. The mixture wastransferred to a separatory funnel and washed with brine. The organiclayer was dried over magnesium sulfate, filtered, and concentrated.Column chromatography [silica gel; eluent hexanes-ethyl acetate (4:1)]provided the desired product (538 mg, 43%).

¹H (CDCl₃) δ(ppm): 1.92-1.98 (m, 2H); 2.33 (t, 2H); 2.64 (t, 2H); 3.19(t, 2H); 3.66 (s, 3H); 4.79 (t, 2H); 7.15 (d, 2H); 7.27 (d, 2H); 7.57(t, 1H); 7.83 (t, 1H); 7.94 (d, 1H); 8.15 (d, 1H); 8.80 (s, 1H). 26.68,33.59, 34.93, 35.03, 51.67, 67.89, 116.48, 123.72, 127.23, 127.82,128.87, 129.24, 133.74, 135.76, 139.90, 151.08, 154.56, 166.89, 174.10.

Example 1D Synthesis of4-{4-[2-(Quinazolin-4-yloxy)ethyl]phenyl}butan-1-ol

To a dry 15 mL flask was added lithium aluminum hydride (233 mg, 6.0mmol) and anhydrous diethyl ether (3 mL). The mixture was cooled with anice bath. A solution of Example 1C (538 mg, 1.54 mmol) in anhydrousdiethyl ether (3 mL) was slowly added with vigorous stirring. The bathwas removed and the slurry was stirred for 15 minutes. The reaction wasquenched with water (0.233 mL), aqueous 15% sodium hydroxide (0.233 mL)and water (0.699 mL). The white solid was filtered and the filtrate wasdried over magnesium sulfate, filtered, and concentrated under reducedpressure to give a clear oil. The oil was then dissolved in anhydrousdichloromethane (10 mL) and manganese(IV) oxide (500 mg, 5.8 mmol) wasadded to the solution. The mixture was stirred for 12 hours. Filtrationthrough diatomaceous earth (Celite®) followed by concentration of thefiltrate under reduced pressure afforded 395 mg of crude product. Columnchromatography [silica gel; eluent pentane-ethyl acetate (2:3)] providedthe desired product (225 mg, 49%). ¹H (CDCl₃) δ(ppm): 1.55-1.61 (m, 2H);1.65-1.68 (m, 2H); 2.61 (t, 2H); 3.17 (t, 2H); 3.64 (t, 2H); 4.79 (t,2H); 7.12 (d, 2H); 7.23 (d, 2H); 7.56 (t, 1H); 7.82 (t, 1H); 7.93 (d,1H); 8.14 (d, 1H); 8.77 (s, 1H). ¹³C (CDCl₃) δ(ppm): 27.52, 32.31,34.89, 35.21, 62.81, 67.74, 116.67, 123.54, 127.08, 127.49, 128.63,128.98, 133.61, 135.23, 140.64, 150.68, 154.29, 166.79.

Example 1E Synthesis of Toluene-4-sulfonic acid4-{4-[2-(quinazolin-4-yloxyethyl]phenyl}butyl ester

To a dry 10 mL flask was added p-toluenesulfonyl chloride (32.5 mg, 0.17mmol), 4-(dimethylamino)pyridine (20.7 mg, 0.17 mmol), Example 1D (50.0mg, 0.16 mmol), anhydrous dichloromethane (1 mL) and triethylamine (17.2mg, 0.17 mmol). The resulting solution was stirred for 2 hours,concentrated under reduced pressure, and purified by columnchromatography [silica gel; eluent pentane-ethyl acetate (1.86:1)] toprovide the desired product (52 mg, 70%). ¹H (CDCl₃) δ(ppm): 1.64-1.68(m, 4H); 2.44 (s, 3H); 2.56 (t, 2H); 3.19 (t, 2H); 4.04 (t, 2H); 4.78(t, 2H); 7.08 (d, 2H); 7.26 (d, 2H); 7.57 (t, 1H); 7.78 (d, 2H); 7.84(t, 1H), 8.14 (d, 1H); 8.80 (s, 1H).

Example 1F Synthesis of 4-{2-[4-(4-Fluorobutyl)phenyl]ethoxy}quinazoline

A dry 5 mL flask was fitted with a reflux condenser. To the flask wasadded potassium fluoride (6.1 mg, 0.1 mmol), kryptofix (40 mg, 0.1 mmol)and anhydrous acetonitrile (0.5 mL). To the resulting solution was addeda solution of Example 1E (25 mg, 0.05 mmol) in anhydrous acetonitrile (1mL). The flask was placed in a 90° C. oil bath. The solution was stirredfor 1 hour. After cooling the reaction mixture was diluted with diethylether, transferred to a separatory funnel, and washed with aqueous 0.1 Nhydrochloric acid, saturated aqueous solution of sodium bicarbonate, andthen brine. The organic layer was dried with magnesium sulfate,filtered, and concentrated under reduced pressure. Column chromatography[silica gel; eluent hexanes-ethyl acetate (3:1)] provided the desiredproduct (10.7 mg, 63%). ¹H (CDCl₃) δ(ppm): 1.65-1.73 (m, 4H); 2.63 (t,2H); 3.17 (t, 2H); 4.40 (t, 1H); 4.48 (t, 1H); 4.77 (t, 2H); 7.13 (d,2H); 7.24 (d, 2H); 7.55 (1H); 7.82 (t, 1H); 7.92 (d, 1H); 8.13 (d, 1H);8.78 (s, 1H). ¹³C (CDCl₃) δ(ppm): 27.19 (d, ⁴J_(CF)=4.5), 30.20 (d,³J_(CF)=19.5), 35.15 (d, ²J_(CF)=27.0), 67.94, 84.17 (d, ¹J_(CF)=163.3),116.93, 123.75, 127.26, 127.84, 128.82, 129.23, 129.42, 133.77, 135.62,138.21, 140.54, 151.08, 154.59. ¹⁹F (CDCl₃, CFCl₃ internal standard)δ(ppm): −218.59 (t of t, J=−27.6, −50.4).

Example 2 Synthesis of Pyridaben Analogs Example 2A Synthesis of Butyricacid 4-phenylbutyl ester

To 4-phenyl-1-butanol (7.0 g, 0.047 mol) was added anhydrousdichloromethane (20 mL). A solution of butyryl chloride (4.79 g, 0.045mol) in anhydrous dichloromethane (20 mL) was added dropwise. Thesolution was stirred for 36 hours. At this point the reaction wasconcentrated under reduced pressure to give a crude oil. Columnchromatography [silica gel; eluent hexanes-ethyl acetate (3:1)] providedthe desired product (9.8 g, 94%) as a clear viscous liquid. ¹H (CDCl₃)δ(ppm): 0.94 (t, 3H); 1.61-1.71 (m, 6H); 2.27 (t, 2H); 2.64 (t, 2H);4.08 (t, 2H); 7.16-7.19 (m, 3H); 7.25-7.29 (m, 2H).

Example 2B Synthesis of 4-(4-Hydroxybutyl)benzoic acid methyl ester

To aluminum chloride (6.7 g, 0.05 mol) in a dry 250 mL round bottomflask was added anhydrous dichloromethane (100 mL). The flask was cooledin a 0° C. ice bath. Oxalyl chloride (6.4 g, 0.05 mol) was addeddropwise to the flask. The mixture was allowed to stir for 5 minutes. Asolution of Example 2A (9.8 g, 0.044 mol) in anhydrous dichloromethane(50 mL) was then added dropwise. The mixture was allowed to stir for 4hours at 0° C. The reaction mixture was poured into a separatory funnelcontaining ice and brine. The organic layer was washed with brine anddried over magnesium sulfate. Filtration and concentration under reducedpressure provided 9.1 g of yellow oil. 9.0 g of this oil was suspendedin methanol and the pH adjusted to 2 and stirred for 48 hours. Thereaction mixture was concentrated under reduced pressure. Columnchromatography [silica gel; eluent hexanes-ethyl acetate (2.57:1)]provided the desired product (2.80 g, 31%) as a clear viscous liquid. ¹H(CDCl₃) δ(ppm): 1.56-1.61 (m, 2H); 1.63-1.73 (m, 2H); 2.67 (t, 2H); 3.64(t, 2H); 3.88 (s, 3H); 7.23 (d, 2H); 7.93 (d, 2H).

Example 2C Synthesis of 4-[4-(tert-Butyldimethylsilanyloxy)butyl]benzoicacid methyl ester

To Example 2B (1.0 g, 4.8 mmol) was added anhydrous dimethylformamide(10 mL), imidazole (0.5 g, 7.2 mmol) and tert-butyldimethylsilylchloride (1.08 g, 7.3 mmol). The solution was stirred in a water bathfor 2 hours. The reaction mixture was diluted with ethyl acetate, pouredinto a separatory funnel, washed with water (20 mL, 5×) then washed witha saturated sodium bicarbonate solution (20 mL, 2×). The organic layerwas dried with magnesium sulfate, filtered, and concentrated underreduced pressure to give the desired product (1.17 g, 75%) which wasused without further purification in the next step.

Example 2D Synthesis of{4-[4-(tert-Butyldimethylsilanyloxy)butyl]phenyl}-methanol

To Example 2C (1.17 g, 3.6 mmol) was added anhydrous diethyl ether (14mL). The solution was cooled to 0° C. with an ice bath. Lithium aluminumhydride (0.28 g, 7.2 mmol) was added to the solution in portions. Themixture was stirred for 1 hour. To the reaction mixture was addeddistilled water (0.28 mL) and the mixture was stirred for 5 minutes.Next was added an aqueous 15% sodium hydroxide solution and the mixturewas stirred for 5 minutes. Lastly distilled water (0.84 mL) was addedand the mixture was stirred for 5 minutes. The white solid was removedby filtration. The filtrate was dried with magnesium sulfate, filtered,and concentrated to give 1.23 g of crude product. Column chromatography[silica gel; eluent hexanes-ethyl acetate (4:1)] provided the desiredproduct (1.02 g, 96%) as a clear viscous liquid.

Example 2E Synthesis of2-tert-Butyl-5-{4-[4-(tert-butyldimethylsilanyloxy)butyl]benzyloxy}-4-chloro-2H-pyridazin-3-one

To a dry 25 mL round bottom flask, fitted with a reflux condenser, wasadded the product of Example 2D (0.41 g, 1.4 mmol),2-tert-butyl-4,5-dichloro-2H-pyridazin-3-one (0.93 g, 4.2 mmol), cesiumcarbonate (1.37 g, 4.2 mmol), and anhydrous dimethylformamide (11 mL).The reaction flask was placed in a 68° C. oil bath and the reaction wasstirred for 12 hours. The reaction flask was removed from the oil bathand allowed to cool. The mixture was diluted with ethyl acetate,transferred to a separatory funnel and washed with water (25 mL, 5×).The organic layer was dried with magnesium sulfate, filtered, andconcentrated under reduced pressure to give 1.3 g of crude product.Column chromatography [silica gel; eluent hexanes-ethyl acetate (9:1)]provided the desired product (594 mg, 89%). ¹H (CDCl₃) δ(ppm): 0.05 (s,6H); 0.90 (s, 9H); 1.64 (s, 9H); 2.65 (t, 2H); 3.64 (t, 2H); 5.23 (s,2H); 7.23 (d, 2H); 7.33 (d, 2H); 7.74 (s, 1H). ¹³C (CDCl₃) δ(ppm):18.57, 26.19, 27.75, 28.09, 32.58, 35.61, 63.14, 66.57, 72.14, 118.46,125.41, 127.44, 129.23, 132.38, 143.72, 154.02, 159.30.

Example 2F Synthesis of2-tert-Butyl-4-chloro-5-[4-(4-hydroxy-butyl)-benzyloxy]-2H-pyridazin-3-one

To the product of Example 2E (594 mg, 1.45 mmol) was added anhydroustetrahydrofuran (3 mL) and a 1.0 M solution of tert-butylammoniumfluoride in tetrahydrofuran (2.9 mL, 2.9 mmol). The solution was stirredfor 1 hour then concentrated under reduced pressure. Columnchromatography [silica gel; eluent pentane-ethyl acetate (1.8:1)]provided the desired product (410 mg, 77%). ¹H (CDCl₃) δ(ppm): 1.61-1.64(m, 11H); 1.67-1.74 (m, 2H); 2.68 (t, 2H); 3.68 (t, 2H); 5.23 (s, 2H);7.23 (d, 2H); 7.33 (d, 2H); 7.74 (s, 1H). ¹³C (CDCl₃) δ(ppm): 27.43,27.86, 32.56, 35.35, 62.74, 66.36, 71.88, 118.27, 125.18, 127.27,128.99, 132.28, 143.17, 153.78, 159.07.

Example 2G Synthesis of Toluene-4-sulfonic acid4-[4-(1-tert-butyl-5-chloro-6-oxo-1,6-dihydro-pyridazin-4-yloxymethyl)-phenyl]-butylester

To a 5 mL round bottom flask was added the product of Example 2F (200mg, 0.55 mmol), p-toluenesulfonyl chloride (125 mg, 0.66 mmol),4-(dimethylamino)pyridine (80 mg, 0.66 mmol), diisopropylethylamine (85mg, 0.66 mmol) and anhydrous dichloromethane (2 mL). The resultingsolution was stirred for 2 hours. The reaction mixture was diluted withethyl acetate, transferred to a separatory funnel and washed with asolution of aqueous 0.1 N hydrochloric acid and then washed with brine.The organic layer was dried with magnesium sulfate, filtered, andconcentrated under reduced pressure to give 299 mg of crude product.Column chromatography [silica gel; eluent pentane-ethyl acetate (3:1)]provided the desired product (197 mg, 69%). ¹H (CDCl₃) δ(ppm): 1.62-1.70(m, 13H); 2.43 (s, 3H); 2.58 (t, 2H); 4.03 (t, 2H); 7.15 (d, 2H);7.29-7.33 (m, 4H); 7.72 (s, 1H); 7.77 (d, 2H). ¹³C (CDCl₃) δ(ppm):21.63, 26.98, 27.86, 28.34, 34.80, 66.37, 70.23, 71, 81, 118.25, 125.12,127.32, 127.87, 128.93, 129.82, 132.48, 133.15, 142.40, 144.72, 153.75,159.05.

Example 2H Synthesis of2-tert-butyl-4-chloro-5-(4-(4-fluorobutyl)benzyl)oxy 3(2H) pyridazinone

The product of Example 2G (57 mg, 0.10 mmol) was dissolved in 1 mLacetonitrile and to this was added a mixture of KF—K222 (1:1; 0.164mmol) dissolved in 1 mL acetonitrile. The entire mixture was thenimmersed in an oil bath at 90° C. and heated at reflux for 15 minutes atwhich point the reaction was shown to be complete by TLC. The volatilecomponents were removed in vacuo and the crude oil was purified by flashsilica gel chromatography (hexanes-ethyl acetate (4:1)) to provide 28 mgof the desired product as a oil which solidified upon standing. ¹H(CDCl₃) δ(ppm): 1.6 (s, 9H), 1.7 (m, 4H), 2.6 (t, 2H), 4.44 (d of t, 2H,J=47.4 & 6 Hz), 5.2 (s, 2H), 7.2 (d, 2H, J=8.4 Hz), 7.3 (d, 2H, J=8.4Hz), 7.71 (s, 1H). ¹³C (CDCl₃) δ(ppm): 26.8 (³J_(CF)=4.65 Hz), 27.8,29.8 (²J_(CF)=19.8 Hz), 35.1, 66.3, 71.8, 83.8 (¹J_(CF)=163.8 Hz),118.2, 125.1, 127.2, 128.9, 132.3, 142.8, 153, 159. ¹⁹F (CDCl₃, CFCl₃ asinternal standard) δ(ppm): −218.6 (t of t, J=−27.6, −50.4).

Example 3 Synthesis of (±)-2-tert-butyl-4-chloro5-(4-(1-fluoro-but-2-oxy)benzyl)oxy-3(2H)-pyridazinone Example 3ASynthesis of (±)-1-tert-butyldimethylsilyloxy-2-hydroxybutane

A 50 mL round bottom flask was charged with (±)-1,2-butanediol (1 g,11.09 mmol) and to it was added dimethylformamide (8 mL) followed bytert-butyldimethylsilyl chloride (2.5 g, 16.64 mmol) and imidazole (1.88g, 27.7 mmol). The reaction mixture was stirred for 10 hours after whichit was diluted with dichloromethane and poured into a separatory funneland washed with water (80 mL) and brine and dried over magnesiumsulfate. After filtration and concentration the crude oil was purifiedby silica gel flash chromatography (hexanes:ethylacetate) to obtain 1 gmof pure desired product in 45% yield. ¹H (CDCl₃) δ(ppm): 3.6 (m, 1H).3.5 (m, 1H), 3.4 (m, 1H), 2.4 (s, 1H), 1.44 (m, 2H), 0.99 (t, 3H), 0.9(s, 9H), 0.06 (s, 6H).

Example 3B Synthesis of (±)-4-(1-tertbutyldimethylsilyloxybut-2-oxy)methylbenzoate

4-Hydroxymethylbenzoate (1.1 g, 7.34 mmol), the product of Example 3A(0.75 g, 3.67 mmol) and triphenylphosphine (1.972 g, 7.34 mmol) wereadded to a round bottom flask and 8 mL tetrahydrofuran was added. Theflask was cooled in an ice bath to 0° C. after whichdiisopropylazodicarboxylate (1.485 g, 7.34 mmol) was added via syringe.The reaction mixture was stirred for 2 hours after which the reactionwas deemed complete by thin layer chromatography. All the solvent wasremoved under reduced pressure and the crude oil directly subjected topurification by silica gel flash chromatography (hexanes:diethyl ether)to obtain 1.0 gm (83%) of the desired compound as a thick oil. ¹H(CDCl₃) δ (ppm): 7.9 (d, 2H), 6.9 (d, 2H), 4.3 (p, 1H, J=5.4 Hz), 3.9(s, 3H), 3.7 (2H), 1.78 (m, 1H), 1.7 (m, 1H), 0.9 (t, 3H, J=7.8 Hz),0.89 (s, 9H), 0.05 (s, 3H), 0.01 (s, 3H). ¹³C (CDCl₃) δ (ppm): 166.8,162.8, 131.5, 122.3, 115.2, 80, 64.5, 51.7, 25.8, 24.1, 18.2, 9.5, −5.3.

Example 3C Synthesis of (±)-4-(1-tertbutyldimethylsilyloxybut-2-oxy)benzylalcohol

To a solution of the product of Example 3B (1 g, 2.95 mmol) in ether (15mL) was added lithium aluminum hydride (0.336 g, 8.8 mmol) and themixture was stirred under nitrogen for 1.5 hours. The reaction wascomplete as shown by TLC by this time and was quenched by addition of0.336 mL water, 0.336 mL of 15% NaOH solution and 1.00 mL water insuccession. The resulting mixture was stirred for an additional 20minutes after which the white precipitate formed was filtered and washedwith ether. The filtrate was then dried over magnesium sulfate.Filtration and removal of the solvent gave 0.50 g (54%) of the desiredproduct as a white solid. ¹H (CDCl₃) δ (ppm): 7.2 (d, 2H), 6.9 (d, 2H),4.3 (p, 1H), 3.77 (d of d, 1H), 3.66 (d of d, 1H), 1.77-1.72 (m, 1H),1.68-1.61 (m, 1H), 1.5 (t, 1H, J=5.4 Hz), 0.9 (t, 3H, J=7.8 Hz), 0.89(s, 9H), 0.04 (s, 3H), 0.01 (s, 3H). ¹³C (CDCl₃) δ (ppm): 158.5, 133,128.4, 116.1, 80.1, 65, 64.5, 25.8, 24.1, 18.2, 9.5, −5.3.

Example 3D Synthesis of (±)-2-tert-butyl 4-chloro5-(4-(1-tertbutyldimethylsilyloxy but-2-oxy)benzyl)oxy3(2H)-pyridazinone

(±)-2-Tert-butyl-4-chloro-5-hydroxy-3(2H)-pyridazinone (0.48 g, 2.417mmol) was charged to a 100 mL round bottom flask and tetrahydrofuran (40mL) was added. After the solution turned clear, Example 3C (0.5 g, 1.611mmol) and triphenylphosphine (0.633 g, 2.417 mmol) were added to theflask and the flask was cooled to 0° C. Diisopropyl azodicarboxylate(0.488 g, 2.417 mmol, 0.468 mL) was then added via a syringe and thereaction was stirred for two hours after which time it was shown to becomplete by TLC. The contents of the flask were then concentrated invacuo and the crude oil obtained was purified by flash chromatographyusing silica gel (hexanes:ethyl acetate) to obtain 0.33 g of the desiredcompound as an oil. ¹H (CDCl₃) δ (ppm): 7.72 (s, 1H), 7.2 (d, 2H), 6.9(d, 2H), 5.2 (s, 2H), 4.2 (p, 1H), 3.75 (d of d, 1H), 3.68 (d of d, 1H),1.75 (m, 2H), 1.65 (m, 1H), 1.6 (s, 9H), 0.99 (t, 3H), 0.85 (s, 9H),0.04 (s, 3H), 0.02 (s, 3H). ¹³C (CDCl₃) δ (ppm): 159.6, 159.3, 154, 129,126.9, 125, 118.5, 116.5, 80.3, 72.1, 66.5, 64.8, 28.1, 26, 24.4, 18.4,9.6, −5.3.

Example 3E Synthesis of(±)-2-tert-butyl-4-chloro-5-(4-(1-hydroxy-but-2-oxy)benzyl)oxy-3(2H)-pyridazinone

To the product of Example 3D (0.3 g, 0.6 mmol) in a 10 mL round bottomflask was added tetrahydrofuran (2 mL). Upon solution,tetrabutylammonium fluoride (1.8 mmol, 1.8 mL, 1M solution in THF) wasadded and the reaction mixture was stirred for 90 minutes. The contentswere then concentrated under reduced pressure and the crude mixturepurified by flash chromatography using silica gel (hexanes:ethylacetate) to obtain 185 mg (80%) of pure desired product. ¹H (CDCl₃) δ(ppm): 7.74 (s, 1H), 7.3 (d, 2H), 6.9 (d, 2H), 5.2 (s, 2H), 4.3 (m, 1H),3.81-3.77 (two br s, 2H), 1.84 (br t, 1H), 1.77-1.69 (m, 2H), 1.64 (s,9H), 0.98 (t, 3H); ¹³C (CDCl₃) δ (ppm): 159.2, 158.9, 153.9, 129.2,127.5, 125.4, 116.6, 80.4, 71.9, 66.5, 64.2, 28, 23.5, 9.7.

Example 3F Synthesis of (±)-2-tert-butyl 4-chloro5-(4-(1-tosyloxy-but-2-oxy)benzyl)oxy 3(2H)-pyridazinone

Into a 10 mL round bottom flask was added the product of Example 3E(0.05 g, 0.13 mmol) followed by dichloromethane (2 mL). Toluenesulfonylchloride (0.075 g, 0.39 mmol), 4-N,N-dimethylaminopyridine (0.048 g,0.39 mmol) and diisopropylethylamine (0.05 g, 0.39 mmol, 68.7 μl) werethen added in succession to the reaction mixture and this was stirredfor 35 minutes. Water was then added to the mixture and the solutionpoured into a separatory funnel and the layers separated. The organiclayer was washed with water and brine and dried over magnesium sulfate.The crude oil obtained after filtration and concentration was purifiedby silica gel flash chromatography (hexanes:ethyl acetate) to obtain 54mg (77%) of the desired compound as a thick colorless oil. ¹H (CDCl₃) δ(ppm): 7.74 (3H, two singlets), 7.3 (m, 4H), 6.8 (d, 2H), 5.2 (s, 2H),4.38 (p, 1H), 4.15 (m, 2H), 2.44 (s, 3H), 1.72 (m, 2H), 1.6 (s, 9H),0.95 (t, 3H); ¹³C (CDCl₃) δ (ppm): 159.2, 158.5, 153.9, 145.1, 133, 130,129, 128.1, 127.2, 125.4, 118.5, 116.5, 71.9, 70.2, 66.6, 28.1, 24.2,21.8, 9.4.

Example 3G Synthesis of (±)-2-tert-butyl-4-chloro5-(4-(1-fluoro-but-2-oxy)benzyl)oxy-3(2H)-pyridazinone

The product of Example 3F (28 mg, 52.4 μmol) was dissolved in 0.5 mLacetonitrile in a 5 mL flask and to this was added a solution ofpotassium fluoride (4.5 mg, 78.6 μmol) and Kryptofix 222 (29.6 mg, 78.6μmol) in 0.5 mL acetonitrile. The above solution was then immersed in aoil bath preheated to 90° C. The reaction was allowed to stir for 90minutes after which all the volatiles were removed under reducedpressure and the crude mixture purified by preparative thin layerchromatography to obtain 13 mg (65%) of pure desired compound. ¹H(CDCl₃) δ (ppm): 7.72 (s, 1H), 7.3 (d, 2H), 6.9 (d, 2H), 5.23 (s, 2H),4.57-4.59 (m, 2H), 4.4 (m, 4H), 1.74 (m, 2H), 1.6 (s, 9H), 1.0 (t, 3H).¹³C (CDCl₃) δ (ppm): 159, 158.7, 153.7, 129, 127.5, 125.2, 118.3, 116.4,83.85 (d, ¹J_(CF)=172.2), 78, 71.1, 66.3, 27.8, 23.2, 9.48. ¹⁹F (CDCl₃,CFCl₃ as internal standard) δ (ppm): −228 (d of t, J=−19, −60 Hz).

Example 4 Synthesis of2-tert-butyl-4-chloro-5-[4-(3-fluoropropoxy)benzyloxy]-2H-pyridazin-3-oneExample 4A Synthesis of 4-(3-hydroxypropoxy)-benzoic acid methyl ester

To a 250 mL flask was added 3-bromo-1-propanol (4.17 g, 0.03 mol),anhydrous dimethylformamide (40 mL), methyl-4-hydroxybenzoate (3.0 g,0.02 mol) and potassium carbonate (4.15 g, 0.03 mol). The flask wasplaced in a 50° C. oil bath and stirred for 12 hours. After cooling thereaction was diluted with ethyl acetate, transferred to separatoryfunnel, washed with aqueous 0.1 N hydrochloric acid, water then brine.The organic layer was dried with magnesium sulfate, filtered, andconcentrated under reduced pressure to give 5.14 g of crude oil. Columnchromatography [silica gel; eluent hexanes-ethyl acetate (1.68:1)]provided the desired product (1.25 g, 30%) as a white powder.

¹H (CDCl₃) δ(ppm): 2.04-2.08 (m, 2H); 3.86-3.88 (m, 5H); 4.17 (t, 2H);6.91 (d, 2H); 7.98 (d, 2H); ¹³C (CDCl₃) δ(ppm): 31.89, 51.81, 59.88,65.50, 114.06, 122.67, 131.57, 162.60, 166.84.

Example 4B Synthesis of4-[3-(tert-Butyldimethylsilanyloxy)propoxy]benzoic acid methyl ester

To a 50 mL flask was added Example 4A (300 mg, 1.4 mmol), anhydrousdimethylformamide (4 mL), tert-butyldimethylsilyl chloride (317 mg, 2.1mmol), and imidazole (146 mg, 2.1 mmol). The resulting solution wasstirred for 2 hours. At this point the reaction was diluted with ethylacetate and transferred to a separatory funnel. The organic phase waswashed with aqueous 0.1 N hydrochloric acid (2×), water (2×), thenbrine. The organic layer was then dried over magnesium sulfate,filtered, and concentrated. Column chromatography [silica gel; eluenthexanes-ethyl acetate (9.5:1)] provided the desired product (413 mg,91%). ¹H (CDCl₃) δ(ppm): 0.03 (s, 6H); 0.87 (s, 9H); 1.97-2.01 (m, 2H);3.79 (t, 2H); 3.87 (s, 3H); 4.11 (t, 2H); 6.90 (d, 2H); 7.97 (d, 2H);¹³C (CDCl₃) δ(ppm): 18.30, 25.89, 32.3, 51.78, 59.27, 64.67, 114.08,122.43, 131.56, 162.90, 166.90.

Example 4C Synthesis of{4-[3-(tert-Butyldimethylsilanyloxy)propoxy]phenyl}methanol

Example 4B (396 mg, 1.22 mmol) was added to a dry 50 mL flask along withanhydrous diethyl ether (10 mL). The flask was lowered into an ice bath.Lithium aluminum hydride (93 mg, 2.44 mmol) was added in portions to thereaction flask. The mixture was allowed to stir in the bath for 2 hours.The reaction was quenched with water (0.093 mL), aqueous 15% sodiumhydroxide (0.093 mL) then water (0.279 mL). The white solid was filteredoff and the filtrate was dried over magnesium sulfate, filtered, andconcentrated to give the desired product (291 mg, 80%). ¹H (CDCl₃)δ(ppm): 0.04 (s, 6H); 0.88 (s, 9H); 1.95-1.99 (m, 2H); 3.79 (t, 2H);4.05 (t, 2H); 4.60 (s, 2H); 6.88-6.89 (m, 2H); 7.25-7.27 (m, 2H);(CDCl₃) δ(ppm): 18.30, 25.91, 32.41, 59.50, 64.57, 65.10, 114.59,128.60, 132.97, 158.75.

Example 4D Synthesis of2-tert-butyl-4-chloro-5-{4-[3-(tert-butyldimethylsilanyloxy)propoxy]benzyloxy}-2H-pyridazin-3-one

To a dry 25 mL flask was added Example 4C (211 mg, 0.71 mmol) andanhydrous tetrahydrofuran (3 mL). The flask was cooled in an ice bath.To the flask was added triphenylphosphine (187 mg, 0.71 mmol) and2-tert-butyl-4-chloro-5-hydroxy-2H-pyridazin-3-one (142 mg, 0.71 mmol).Lastly, diisopropyl azodicarboxylate (144 mg, 0.71 mmol) was added. Thereaction mixture was allowed to stir in the ice bath for 1 hour. At thispoint the mixture was diluted with diethyl ether and transferred to aseparatory funnel. The organic solution was washed with water and thenbrine, dried over magnesium sulfate, filtered, and concentrated underreduced pressure. Column chromatography [silica gel; eluenthexanes-ethyl acetate (9:1)] provided the desired product (106 mg, 31%).¹H (CDCl₃) δ(ppm): 0.03 (s, 6H); 0.87 (s, 9H); 1.62 (s, 9H); 1.95-1.99(m, 2H); 3.79 (t, 2H); 4.06 (t, 2H); 5.23 (s, 2H); 6.91-6.92 (m, 2H);7.30-7.31 (m, 2H); 7.72 (s, 1H); ¹³C (CDCl₃) δ(ppm): 18.29, 25.90,27.87, 32.34, 59.41, 64.63, 66.30, 71.89, 114.90, 118.34, 125.34,126.68, 128.92, 153.79, 159.07, 159.55.

Example 4E Synthesis of2-tert-butyl-4-chloro-5-[4-(3-hydroxypropoxy)-benzyloxy]-2H-pyridazin-3-one

To a dry 10 mL flask was added Example 4D (100 mg, 0.21 mmol) along withanhydrous tetrahydrofuran (2 mL). To the flask was added a solution of1.0 M tetrabutylammonium fluoride in tetrahydrofuran (0.42 mL, 0.42mmol). The solution was stirred for 2 hours. At this point the reactionwas concentrated under reduced pressure. Preparatory thin layerchromatography [silica gel; eluent hexanes-ethyl acetate (1:1)] providedthe desired product (57.8 mg, 76%). ¹H (CDCl₃) δ(ppm): 1.62 (s, 9H);2.02-2.06 (m, 2H); 3.86 (t, 2H); 4.13 (t, 2H); 5.30 (s, 2H); 6.92-6.93(m, 2H); 7.31-7.32 (m, 2H); 7.71 (s, 1H); ¹³C (CDCl₃) δ(ppm): 27.87,31.97, 60.24, 65.67, 66.34, 71.81, 114.91, 118.37, 125.31, 127.06,128.98, 153.76, 159.07, 159.27.

Example 4F Synthesis of toluene-4-sulfonic acid3-[4-(1-tert-butyl-5-chloro-6-oxo-1,6-dihydro-pyridazin-4-yloxymethyl)phenoxy]propylester

To a dry 5 mL flask was added Example 4E (40 mg, 0.11 mmol),4-methyl-benzenesulfonyl chloride (31 mg, 0.16 mmol),4-(dimethylamino)pyridine (20 mg, 0.16 mmol), diisopropylethylamine(16.6 mg, 0.16 mmol) and anhydrous dichloromethane (0.6 mL). Theresulting solution was stirred for 1 hour. The reaction mixture wasconcentrated under reduced pressure. Preparatory thin layerchromatography [silica gel; eluent pentane-ethyl acetate (3:2)] providedthe desired product (18.6 mg, 33%). ¹H (CDCl₃) δ(ppm): 1.62 (s, 9H);2.09-2.13 (m, 2H); 2.37 (s, 3H); 3.95 (t, 2H); 4.23 (t, 2H); 5.22 (s,2H); 6.78 (d, 2H); 7.23 (d, 2H); 7.29 (d, 2H); 7.73-7.75 (m, 3H). ¹³C(CDCl₃) δ(ppm): 21.60, 27.85, 28.81, 63.15, 66.35, 66.87, 71.75, 114.76,118.27, 125.18, 127.11, 127.83, 128.94, 129.80, 132.79, 144.80, 163.72,158.90, 159.03.

Example 4G Synthesis of2-tert-butyl-4-chloro-5-[4-(3-fluoropropoxy)benzyloxy]-2H-pyridazin-3-one

To a scintillation vial containing a suspension of Example 4F (4.5 mg,8.64×10⁻³ mmol) in anhydrous acetonitrile (0.25 mL) was added a solutionof potassium fluoride (1.6 mg, 4.07×10⁻² mmol) and kryptofix (15.0 mg,4.07×10⁻² mmol) in anhydrous acetonitrile (0.25 mL). The vial was cappedand lowered into a 90° C. oil bath. The reaction was allowed to stir for40 minutes. The reaction was cooled and concentrated under reducedpressure. Preparatory thin layer chromatography [silica gel; eluentpentane-ethyl acetate (3:2)] provided the desired product (0.8 mg, 25%).¹H (CDCl₃) δ(ppm): 1.62 (s, 9H); 2.14-2.20 (m, 2H); 4.09-4.11 (m, 2H);4.60 (t, 1H); 4.68 (t, 1H); 5.24 (s, 2H); 6.92 (d, 2H); 7.32 (d, 2H);7.72 (s, 1H); ¹⁹F (CDCl₃, CFCl₃ as internal standard) δ(ppm): −222.66 (tof t, J=28.2, −50.4).

Example 5 Synthesis of2-tert-butyl-4-chloro-5-[4-(2-fluoro-ethoxymethyl)-benzyloy]-2H-pyridazin-3-oneExample 5A Synthesis of 4-(2-hydroxyethoxymethyl)benzoic acid methylester

To a two-neck round bottom flask, which was equipped with a Dewarcondenser, a solution of 4-hydroxymethylbenzoic acid methyl ester (2.50g, 0.015 mol) in anhydrous dichloromethane (30 mL) was cooled to −10° C.in a salt/ice bath. Ethylene oxide (1.10 mL) was added to the cooledstirring solution dropwise followed by the addition of boron trifluorideetherate (0.51 ml). The reaction mixture was stirred for 45 minutes andthen warmed to room temperature for 30 minutes to boil off any excess ofethylene oxide in the reaction mixture. The reaction mixture was thendiluted with brine. The aqueous layer was extracted with dichloromethane(3 times). All of the organic layers were combined, dried over Na₂SO₄,filtered, and concentrated to provide an oil. The crude material waspurified using silica gel chromatography (4:1 pentane:ethyl acetate) toprovide the desired product (537 mg, 2.56 mmol) in 17% yield. ¹H(CDCl₃8.36, 600 MHz): δ (2H, d, J=8.4 Hz), 7.41 (2H, d, J=8.5 Hz), 4.62(3H, s), 3.92 (2H, s), 3.78 (m, 2H), 3.63 (2H, m); ¹³C (CDCl₃167.1,143.5, 130.0, 129.8, 127.5, 72.9, 72.0, 150 MHz): δ 62.1, 52.3.

Example 5B Synthesis of4-[2-(tert-butyldimethylsilanyloxy)ethoxymethyl]benzoic acid methylester

To a solution of the product of Example 5A (544.5 mg, 2.59 mmol) inanhydrous DMF (26 mL) was added imidazole (264 mg, 3.89 mmol) andTBDMS-Cl (586 mg, 3.89 mmol). The reaction mixture stirred at roomtemperature overnight and was quenched with water. The aqueous layer wasextracted with ethyl acetate (3×). All combined organic layers weredried over Na₂SO₄, filtered, and concentrated. The crude material waspurified using silica gel chromatography (4:1 pentane:ethyl acetate) toprovide the desired product (677.5 mg, 2.19 mmol) in 84% yield. ¹H(CDCl₃8.01, 600 MHz): δ (2H, d, J=8.3 Hz), 7.42 (2H, d, J=8.4 Hz), 4.63(2H, s), 3.91 (2H, s), 3.82 (2H, t, J=5.0), 3.58 (2H, t, J=5.1 Hz), 0.91(9H, s), 0.07 (6H, s); ¹³C (CDCl₃166.5, 143.5, 129.2, 128.8, 126.5,72.1, 71.6, 150 MHz): δ 62.3, 51.5, 25.4, 17.9, −5.8.

Example 5C Synthesis of{4-[2-(tert-butyldimethylsilanyloxy)ethoxymethyl]phenyl}methanol

To a solution of the product of Example 5B (670 mg, 2.18 mmol) dissolvedin anhydrous THF (22 mL) was added a solution of LAH (1.0 M solution inTHF, 2.18 mL, 2.18 mmol) dropwise. After completion of addition thereaction mixture was stirred at room temperature for 3 hours. Thereaction mixture was diluted with water. The aqueous layer was extractedwith ethyl acetate (3×). All combined organic layers were dried overNa₂SO₄, filtered, and concentrated to provide an oil (587 mg, 1.98mmol), which was used in the next step without any further purification(91% yield). ¹H (CDCl₃7.34 (4H, s), 4.68 (2H, s), 4.57 (2H, s), 3.80,600 MHz): δ (2H, t, J=5.2 Hz), 3.56 (2H, t, J=5.3 Hz), 1.69 (1H, br s),0.90 (9H, s), 0.07 (6H, s); ¹³C (CDCl₃ 140.4, 138.3, 128.0, 127.2, 73.2,71.9, 65.4, 150 MHz): δ 63.0, 26.2, 18.6, −5.0,

Example 5D Synthesis of2-tert-butyl-5-{4-[2-(tert-butyldimethylsilanyloxy)ethoxymethyl]benzyloxy}-4-chloro-2H-pyridazin-3-one

To solution of the product of Example 5C (437 mg, 1.48 mmol) and2-tert-butyl-4-chloro-5-hydroxy-2H-pyridazin-3-one (250 mg, 1.23 mmol)dissolved in anhydrous THF (12 mL) was added solid PPh₃ (485 mg, 1.85mmol) and diisopropyl azodicarboxylate (DIAD, 0.358 mL, 1.85 mmol).After completion of addition the reaction mixture continued to stir atroom temperature. After 20 hours, the reaction mixture was diluted withwater. The aqueous layer was separated and extracted with ethyl acetate(3×). All combined organic layers were dried over Na₂SO₄, filtered, andconcentrated to provide an oil. The crude material was purified usingsilica gel chromatography (4:1 pentane:ethyl acetate) to provide thedesired product 528 mg, 1.10 mmol) in 89% yield. ¹H (CDCl₃ 7.70 (1H, s),7.38 (4H, m), 5.30 (2H, s), 4.58, 600 MHz): δ (2H, s), 3.80 (2H, t,J=5.4 Hz), 3.57 (2H, t, J=5.4 Hz), 1.63 (9H, br s), 0.90 (9H, s), 0.07(6H, s); ¹³C (CDCl₃159.0, 153.7, 138.8, 134.4, 128.3, 127.3, 150 MHz): δ125.1, 118.5, 72.8, 71.7, 71.6, 66.4, 61.9, 29.7, 27.9, 25.6, −5.1; HRMScalcd for C₂₄H₃₇ClN₂O₄Si: 481.228389, found 481.2282.

Example 5E Synthesis of2-tert-butyl-4-chloro-5-[4-(2-hydroxyethoxymethyl)benzyloxy]-2H-pyridazin-3-one

To a solution of the product of Example 5D (528 mg, 1.09 mmol) dissolvedin anhydrous THF (11 mL) was added a solution of TBAF (1.0 M solution inTHF, 1.65 mL, 1.65 mmol) dropwise. After completion of addition thereaction was stirred at room temperature for 1 hour and then quenchedwith water. The aqueous layer was separated and extracted with ethylacetate (3×). All combined organic layers were dried over Na₂SO₄,filtered, and concentrated to provide an oil. The crude material waspurified using silica gel chromatography (4:1 hexanes:ethyl acetate) toprovide the desired product (311 mg, 0.850 mmol) in 78% yield. ¹H(CDCl₃, 600 MHz): δ 7.70 (1H, s), 7.38 (4H, m), 5.30 (2H, s), 4.56 (2H,s), 3.76 (2H, t, J=4.9 Hz), 3.60 (2H, t, J=4.8 Hz), 2.00 (1H, br s),1.61 (9H, br s); ¹³C (CDCl₃159.0, 153.6, 150 MHz): δ 138.8, 134.4,128.2, 127.2, 125.1, 118.3, 72.8, 71.6, 71.6, 66.4, 61.9, 27.8; HRMScalcd for C₁₈H₂₃ClN₂O₄: 367.141911, found 367.1419.

Example 5F Synthesis of toluene-4-sulfonic acid2-[4-(1-tert-butyl-5-chloro-6-oxo-1,6-dihydro-pyridazin-4-yloxymethyl)-benzyloxy]-ethylester

To a solution of the product of Example 5E (200 mg, 0.546 mmol)dissolved in anhydrous dichloromethane (5.50 mL) was added TsCl (125 mg,0.656 mmol), DMAP (100 mg, 0.819 mmol) and triethylamine (0.091 mL,0.656 mmol). The reaction mixture continued stirring at roomtemperature. After 22 hours the reaction mixture was diluted with water.The aqueous layer was separated and extracted with ethyl acetate (3×).All combined organic layers were dried over Na₂SO₄, filtered, andconcentrated to provide an oil. The crude material was purified usingsilica gel chromatography (3:2 pentane:ethyl acetate) to provide thedesired product (232 mg, 0.447 mmol) in 82% yield. ¹H (CDCl₃7.79, 600MHz): δ (2H, d, J=8.3 Hz), 7.71 (1H, s), 7.38 (2H, d, J=8.2 Hz), 7.32(4H, m), 5.30 (2H, s), 4.50 (2H, s), 4.21 (2H, m), 3.69 (2H, m), 2.43(3H, s), 1.63 (9H, br s); ¹³C (CDCl₃ 159.0, 153.7, 144.8, 138.8, 150MHz): δ 134.4, 133.1, 129.8, 128.1, 128.0, 127.2, 125.1, 118.4, 72.8,71.7, 69.2, 67.8, 66.4, 27.9, 21.6; HRMS calcd for C₂₅H₂₉ClN₂O₆:521.150762, found 521.1503.

Example 5G Synthesis of2-tert-butyl-4-chloro-5-[4-(2-fluoro-ethoxymethyl)-benzyloy]-2H-pyridazin-3-one

To a solution of the product of Example 5F (50 mg, 0.096 mmol) inanhydrous acetonitrile (1.0 mL) was added KF (11.2 mg, 0.192 mmol) andKryptofix (72.4 mg, 0.192 mmol). After completion of addition thereaction mixture was heated to 90° C. After 10 minutes, the reactionmixture was cooled down to room temperature and diluted with water. Theaqueous layer was separated and extracted with ethyl acetate (3×). Allcombined organic layers were dried over Na₂SO₄, filtered, andconcentrated to provide an oil. The crude material was purified usingsilica gel chromatography (4:1 pentane:ethyl acetate) to provide thedesired product (28 mg, 0.076 mmol) in 79% yield. ¹H (DMSO-d₆, 600 MHz):δ 8.22 (1H, s), 7.45 (2H, d, J=8.20 Hz), 7.39 (2H, d, J=8.24 Hz), 5.42(2H, s), 4.60 (1H, m), 4.54 (2H, s), 4.52 (1H, m), 3.71 (1H, m), 3.66(1H, m), 1.57 (9H, s); ¹³ 157.8, 153.8, 138.6, C (DMSO-d6, 150 MHz): δ134.6, 127.8, 127.7, 126.2, 115.6, 83.5 (82.4), 71.6, 71.2, 69.1 (69.0),65.3, 27.4; ¹⁹F (DMSO-d₆-221.74 (1F, m)., 564 MHz): δ HRMS calcd forC₁₈H₂₂ClFN₂O₃: 369.137575, found 369.1377.

Example 6 Synthesis of2-tert-butyl-4-chloro-5-[4-(2-fluoropropoxy)benzyloy]-2H-pyridazin-3-oneExample 6A Synthesis of 1-(4-hydroxymethylphenoxy)propan-2-one

To a stirred solution of 4-hydroxybenzyl alcohol (1.0 g, 8.06 mmol) inacetone (80 mL) was added potassium carbonate (1.34 g, 9.68 mmol) andchloroacetone (0.771 mL, 9.68 mmol). After completion of addition thereaction mixture was heated to reflux. After 20 hours the reactionmixture was cooled down to room temperature and the solvent was removed.Water and ethyl acetate were added to the crude material. The aqueouslayer was separated and extracted with ethyl acetate (3×, 100 mL). Allcombined organic layers were dried over Na₂SO₄, filtered, andconcentrated to provide an oil. The crude material was purified usingsilica gel chromatography (gradient from 4:1 to 1:1 pentane:ethylacetate) to provide the desired product (0.981 g, 5.45 mmol) in 98%yield. ¹H (CDCl₃, 600 MHz): δ 7.30 (2H, d, J=8.7 Hz), 6.87 (2H, d, J=8.7Hz), 4.63 (2H, d, J=5.7 Hz), 4.54 (2H, s), 2.27 (3H, s), 1.66 (1H, t,J=5.8 Hz); ¹³C (CDCl₃, 150 MHz): δ 205.7, 157.3, 134.3, 128.8, 114.6,73.1, 64.8, 26.6.

Example 6B Synthesis of 1-(4-hydroxymethyl-phenoxy)-propan-2-ol

To a solution of 1-(4-hydroxymethylphenoxy)-propan-2-one (1.26 g, 6.99mmol) dissolved in methanol (60 mL) was added solid NaBH₄ (0.32 g, 8.39mmol). After completion of addition the reaction mixture was stirred atroom temperature overnight. The reaction mixture was diluted with water,and the aqueous layer was extracted with ethyl acetate (3×). Allcombined organic layers were dried over Na₂SO₄, filtered, andconcentrated to provide an oil (1.24 g, 6.81 mmol), which was used inthe next step without any further purification (98% yield). ¹H(CDCl₃7.29, 600 MHz): δ (2H, d, J=8.4 Hz), 6.90 (2H, d, J=8.5 Hz), 4.62(2H, s), 4.21 (1H, m), 3.94 (1H, dd, J=9.2, 3.1 Hz), 3.82 (1H, m), 1.29(3H, d, J=6.4 Hz).

Example 6C Synthesis of2-tert-butyl-4-chloro-5-[4-(2-hydroxypropoxy)benzyloxy]-2H-pyridazin-3-one

To solution of the product of Example 6B (269 mg, 1.48 mmol) and2-tert-butyl-4-chloro-5-hydroxy-2H-pyridazin-3-one (250 mg, 1.23 mmol)dissolved in anhydrous THF (18.5 mL) was added solid PPh₃ (485 mg, 1.85mmol) and DIAD (0.358 mL, 1.85 mmol). After completion of addition thereaction mixture continued to stir at room temperature. After 20 hours,the reaction mixture was diluted with water. The aqueous layer wasseparated and extracted with ethyl acetate (3×). All combined organiclayers were dried over Na₂SO₄, filtered, and concentrated to provide anoil. The crude material was purified using silica gel chromatography(1:1 pentane:ethyl acetate) to provide the desired product (234 mg,0.634 mmol) in 51% yield. ¹H (CDCl₃ 7.71 (1H, s), 7.33 (2H, d, 600 MHz):δ J=8.7 Hz), 6.94 (2H, d, J=8.7 Hz), 5.24 (2H, s), 4.19 (1H, m), 3.95(1H, dd, J=9.2, 3.1 Hz), 3.81 (1H, dd, J=9.2, 7.7 Hz), 1.62 (9H, s) 1.29(3H, d, J=6.4 Hz).

Example 6D Synthesis of toluene-4-sulfonic acid2-[4-(1-tert-butyl-5-chloro-6-oxo-1,6-dihydro-pyridazin-4-yloxymethyl)-phenoxy]-1-methyl-ethylester

To a solution of the product of Example 6C (200 mg, 0.546 mmol)dissolved in anhydrous dichloromethane (6.0 mL) was added TsCl (125 mg,0.656 mmol), DMAP (100 mg, 0.819 mmol) and triethylamine (0.0914 mL,0.656 mmol). The reaction mixture continued stirring at roomtemperature. After 22 hours the reaction mixture was diluted with water.The aqueous layer was separated and extracted with ethyl acetate (3×).All combined organic layers were dried over Na₂SO₄, filtered, andconcentrated to provide an oil. The crude material was purified usingsilica gel chromatography (70:30 pentane:ethyl acetate) to provide thedesired product (166 mg, 0.319 mmol) in 58% yield. ¹H (CDCl₃7.80 (2H, d,600 MHz): δ J=8.3 Hz), 7.72 (1H, s), 7.32 (2H, d, J=7.9 Hz), 7.29 (2H,d, J=8.7 Hz), 6.74 (2H, d, J=8.7 Hz), 5.22 (2H, s), 4.19 (1H, m), 4.02(1H, dd, J=10.4, 6.0 Hz), 3.93 (1H, dd, J=10.4, 4.5 Hz), 2.44 (3H, s),1.63 (9H, s) 1.42 (3H, d, J=6.5 Hz); ¹³C (CDCl₃ 158.9, 150 MHz): δ158.3, 153.6, 144.6, 133.8, 129.6, 128.8, 127.8, 127.4, 125.1, 118.0,114.7, 76.8, 71.5, 69.7, 66.2, 27.7, 21.5, 17.6; HRMS calcd forC₂₅H₂₉ClN₂O₆S: 521.150762, found 521.1505.

Example 6E Synthesis of2-tert-butyl-4-chloro-5-[4-(2-fluoropropoxy)benzyloy]-2H-pyridazin-3-one

To a solution of the product of Example 6E (50 mg, 0.096 mmol) inanhydrous acetonitrile (1.0 mL) was added KF (11.2 mg, 0.192 mmol) andKryptofix (72.4 mg, 0.192 mmol). After completion of addition thereaction mixture was heated to 90° C. After 40 minutes, the reactionmixture was cooled down to room temperature and diluted with water. Theaqueous layer was separated and extracted with ethyl acetate (3×). Allcombined organic layers were dried over Na₂SO₄, filtered, andconcentrated to provide an oil. The crude material was purified using apreparative silica gel thin layer chromatography plate (4:1pentane:ethyl acetate) to isolate the desired product (12.5 mg, 0.034mmol) in 41% yield (based on recovered starting material), in additionto unreacted starting material (5.8 mg, 0.011 mmol). ¹H (CDCl₃, 600MHz): δ 7.73 (1H, s) 7.34 (2H, d, J=8.6 Hz), 6.95 (2H, d, J=8.6 Hz),5.25 (2H, s), 5.06-4.96 (1H, m), 4.06 (2H, m), 1.63 (9H, s) 1.47 (3H,dd, J=6.4, 23.6 Hz); ¹³C (DMSO-d₆, 158.4, 157.8, 153.9, 129.8, 127.6,126.2, 115.5, 114.6, 89.0 150 MHz): δ (88.0), 71.2, 70.4 (70.3), 65.3,27.4, 16.9 (16.8); ¹⁹F (DMSO-d₆, −178.20 (1F, m); 564 MHz): δ HRMS calcdfor C₁₈H₂₂ClFN₂O₃: 369.137575, found 369.1370.

Example 7 Synthesis of2-tert-butyl-4-chloro-5-[4-(3-fluorobutyl)benzyloxy]-2H-pyridazin-3-oneExample 7A Synthesis of 4-(3-oxobutyl)benzoic acid methyl ester

To a solution of methyl-4-bromobenzoate (1.0 g, 4.65 mmol) intriethylamine (13 mL) was added 3-buten-2-ol (1 mL, 11.63 mmol),palladium (II) acetate (0.104 g, 0.465 mmol), and thentriphenylphosphine (0.244 g, 0.93 mmol). The reaction was stirred in a75° C. oil bath overnight under nitrogen atmosphere. Monitoring by TLC(3:1 hexane:ethyl acetate) showed the product and aryl bromide. Thereaction was cooled to room temperature and then concentrated. Water wasthen added followed by extraction with ethyl acetate. The organic layerwas washed with water and brine, dried over Na₂SO₄, filtered andconcentrated. The crude product was purified by flash columnchromatography (5:1 to 3:1 hexane:ethyl acetate) to obtain the product(250 mg, 26% yield). ¹H NMR (600 MHz, CDCl₃): δ 7.95 (d, 2H, J=8.4 Hz),7.25 (d, 2H, J=8.4 Hz), 3.90 (s, 3H), 2.95 (t, 2H, J=7.45 Hz), 2.77 (t,2H, J=7.68 Hz), 2.14 (s, 3H).

Example 7B Synthesis of2-tert-butyl-4-chloro-5-[4-(3-hydroxybutyl)benzyloxy]-2H-pyridazin-3-one

To a solution of the product of Example 7A (505 mg, 2.447 mmol) in THF(19 mL) at 0° C. was added a 1M solution (in THF) of lithium aluminumhydride (12.2 mL, 12.237 mmol) dropwise. After completion of additionthe ice bath was removed and the reaction was stirred at roomtemperature for 1 hour under nitrogen atmosphere. Then, in succession,was added water (183 μL), 15% NaOH solution (183 μL), and water (548μL). The reaction stirred for an additional 15 minutes before it wasfiltered and washed with THF. The filtrate was then concentrated underreduced pressure to obtain 4-(4-hydroxymethyl-phenyl)butan-2-ol as abrown oil (314 mg, 71% yield). Then to a solution of2-tert-butyl-4-chloro-5-hydroxy-2H-pyridazin-3-one (234 mg, 1.155 mmol)in THF (45 mL) was added 4-(4-hydroxymethylphenyl)butan-2-ol (312 mg,1.732 mmol), triphenylphosphine (454 mg, 1.732 mmol), and thendiisopropyl azodicarboxylate (DIAD, 335 μL, 1.732 mmol). The reactionwas stirred at room temperature overnight under nitrogen atmosphere.Thin layer chromatography (100% ethyl acetate) indicated consumption ofthe pyridazinone starting material and the reaction was concentrated.The crude material was purified by flash column chromatography (4:1hexane:ethyl acetate to 100% ethyl acetate) to obtain a clear oil (200mg, 48% yield). ¹H NMR (600 MHz, CDCl₃): δ 7.73 (s, 1H), 7.32 (d, 2H,J=8.0), 7.24 (d, 2H, J=8.0), 5.30 (s, 1H), 5.27 (s, 2H), 3.83 (m, 1H),2.80-2.76 (m, 1H), 2.71-2.66 (m, 1H), 1.63 (s, 9H), 1.23 (d, 3H, J=6.2);¹³C (CDCl₃ 159.3, 153.9, 143.2, 132.5, 129.2, 127.6, 125.4, 150 MHz): δHRMS calcd for C 118.5, 73.4, 67.6, 66.6, 40.9, 32.0, 28.1, 23.9.₁₉H₂₅ClN₂O₃: 365.162647, found 365.1624.

Example 7C Synthesis of toluene-4-sulfonic acid3-[4-(1-tert-butyl-5-chloro-6-oxo-1,6-dihydro-pyridazin-4-yloxymethyl)-phenyl]-1-methylpropylester

To a solution of the product of Example 7B (200 mg, 0.548 mmol) inpyridine (10 mL) was added p-toluenesulfonyl chloride (209 mg, 1.096mmol). The reaction was stirred at room temperature overnight undernitrogen atmosphere. Monitoring by LC-MS showed a 1:1 mixture ofstarting material and product. The reaction was diluted with ethylacetate and washed with 5% CuSO₄ until a light blue aqueous solution wasmaintained. The organic layer was then dried over Na₂SO₄, filtered, andconcentrated. The crude material was purified by flash columnchromatography (3:1 hexane:ethyl acetate to 100% ethyl acetate) torecover the starting material (90 mg) and the product as a clear oil (74mg, 47% yield based on recovered starting material). ¹H NMR (600 MHz,CDCl₃): 7.80 (d, 2H, J=8.3 Hz), 7.72 (s, 1H), 7.33 (d, 2H, J=8.0 Hz),7.30 (d, 2H, J=8.1 Hz), 7.13 (d, 2H, J=8.1 Hz), 5.27 (s, 2H), 4.66 (m,1H), 2.65 (m, 1H), 2.54 (m, 1H), 2.45 (s, 3H), 1.94 (m, 1H), 1.81 (m,1H), 1.63 (s, 9H), 1.26 (s, 3H).

Example 7D Synthesis of2-tert-butyl-4-chloro-5-[4-(3-fluorobutyl)benzyloxy]-2H-pyridazin-3-one

To a solution of the product of Example 7C (18.2 mg, 0.035 mmol) inacetonitrile (400 μL) was added potassium fluoride (4.1 mg, 0.070 mmol)and K222 (26.4 mg, 0.070 mmol). The reaction was stirred at 90° C. for20 minutes under nitrogen atmosphere, monitoring by LC-MS. The reactionwas then cooled to room temperature and concentrated under reducedpressure. The crude material was purified by preparative thin layerchromatography (4:1 hexane:ethyl acetate as eluant) to obtain theproduct as an oil (5 mg, 39% yield). ¹H NMR (600 MHz, CDCl₃): δ 7.70 (s,1H), 7.34 (d, 2H, J=7.9 Hz), 7.24 (d, 2H, J=8.0 Hz), 5.28 (s, 2H),4.71-4.60 (m, 2H), 2.84-2.80 (m, 1H), 2.73-2.69 (m, 1H), 2.02-1.93 (m,1H), 1.87-1.77 (m, 1H), 1.63 (s, 9H), 1.35 (dd, 3H, J=6.2 and 23.9 Hz);¹³C (CDCl₃159.1, 153.8, 150 MHz): δ 142.4, 132.5, 129.0, 127.4, 125.2,118.3, 90.4 (89.3), 71.9, 66.3, 38.5 (38.4), 31.1 (31.0), 27.9, 21.1(21.0); ¹⁹F (CDCl₃-174.7, 564 MHz): δ (1F, m); HRMS calcd forC₁₉H₂₃ClFN₂O₂: 367.158310, found 367.1582.

Example 8 Synthesis of toluene-4-sulfonic acid2-[4-(1-tert-butyl-5-chloro-6-oxo-1,6-dihydro-pyridazin-4-yloxymethyl)-benzyloxy]ethylester hexadeuterate Example 8A Synthesis of4-[2-hydroxyethoxymethyl]benzoic acid methyl ester tetradeuterate

To a flame-dried 2-neck flask was added a solution ofmethyl-4-(hydroxymethyl)benzoate (2.5 g, 15 mmol) in dichloromethane (30mL). The reaction was purged with nitrogen and brought to −5° C. A dewarcondenser (also flame-dried) containing a dry ice/acetone bath (−78° C.)was affixed to the flask and ethylene oxide-tetradeuterate was added(˜55 drops). Then BF₃.Et₂O (510 μL, 0.0041 mmol) was added dropwise andthe reaction stirred at −5° C. for 35 minutes under nitrogen atmosphere.Monitoring by TLC (100% ethyl acetate) showed complete consumption ofthe starting material. The reaction was warmed to room temperature andvented to remove any excess ethylene oxide gas. The reaction was thendiluted with brine and extracted with dichloromethane (2 times). Thecombined organics were dried over Na₂SO₄, filtered, and concentratedunder reduced pressure to obtain a crude oil. Purification by flashcolumn chromatography (4:1 pentane:ethyl acetate) provided the productas a clear oil (520 mg, 16% yield). ¹H NMR (600 MHz, CDCl₃) δ 8.02 (d,2H, J=8.2 Hz), 7.41 (d, 2H, J=8.1 Hz), 4.62 (s, 2H), 3.92 (s, 3H); ¹³CNMR (150 MHz, CDCl₃167.1, 143.5, 130.8) δ 129.9, 127.5, 72.8, 52.4.

Example 8B Synthesis of4-[2-(tert-butyldimethylsilanyloxy)ethoxymethyl]benzoic acid methylester tetradeuterate

To a solution of the product of Example 8A (500 mg, 2.334 mmol) in DMF(23 mL) was added tert-butyldimethylsilyl chloride (528 mg, 3.501 mmol)and imidazole (238 mg, 3.501). The reaction was stirred at roomtemperature for 5 hours under nitrogen atmosphere, monitoring by TLC(3:1 pentane:ethyl acetate). Another 0.5 eq. portion oftert-butyldimethylsilyl chloride (176 mg) and imidazole (79 mg) wereadded and the resultant mixture stirred at room temperature overnight.The majority of the starting material was consumed in 16 hours, asindicated by thin layer chromatography. The reaction was diluted withwater and extracted with ethyl acetate (2 times). The combined organiclayers were dried over Na₂SO₄, filtered, and concentrated under reducedpressure to obtain a crude oil which was purified by passage throughthick pad of silica gel (3:1 pentane:ethyl acetate) to obtain theproduct as a clear oil (602 mg). ¹H NMR (600 MHz, CDCl₃): 8.00 (d, 2H,J=8.3 Hz), 7.40 (d, 2H, J=8.5 Hz), 4.62 (s, 2H), 3.90 (s, 3H), 0.90 (s,9H), 0.06 (s, 6H).

Example 8C Synthesis of{4-[2-(tert-butyldimethylsilanyloxy)ethoxymethyl]phenyl}methanolhexadeuterate

To a solution of the product of Example 8B (610 mg, 1.857 mmol) in THF(19 mL) at 0° C. was added a 1M solution (in THF) of lithium aluminumdeuteride (1.9 mL, 1.857 mmol) dropwise. After completion of additionthe ice bath was removed and the reaction was stirred at roomtemperature for 3.5 hours under nitrogen atmosphere, monitoring by TLC(3:1 pentane:ethyl acetate). The reaction was then diluted with waterand extracted with ethyl acetate (2 times). The combined organics weredried over Na₂SO₄, filtered, and concentrated under reduced pressure toobtain a clear oil (482 mg, 86% yield). The material was taken to thenext step without further purification. ¹H NMR (600 MHz, CDCl₃): 7.33(s, 4H), 4.56 (s, 2H), 0.89 (s, 9H), 0.06 (s, 6H).

Example 8D Synthesis of2-tert-butyl-4-chloro-5-{4-[2-(tert-butyldimethylsilanyloxy)ethoxymethyl]benzyloxy}-2H-pyridazin-3-onehexadeuterate

To a solution of 2-tert-butyl-4-chloro-5-hydroxy-2H-pyridazin-3-one (212mg, 1.047 mmol) in THF (15 mL) was added the product of Example 8C (475mg, 1.570 mmol), triphenylphosphine (412 mg, 1.570 mmol), and thendiisopropyl azodicarboxylate (DIAD, 304 μL, 1.570 mmol). The reactionwas stirred at room temperature for 2 hours under nitrogen atmosphere.Thin layer chromatography (1:1 hexane:ethyl acetate) indicatedconsumption of the pyridazinone starting material and the reaction wasconcentrated in vacuo. The crude material was purified by flash columnchromatography (90:10 pentane:ethyl acetate) to obtain a clear oil (336mg, 66% yield). ¹H NMR (600 MHz, CDCl₃): 7.70 (s, 1H), 7.39 (m, 4H),4.58 (s, 2H), 1.63 (s, 9H), 0.90 (s, 9H), 0.07 (s, 6H); HRMS calcd forC₂₄H₃₁D₆ClN₂O₄Si: 509.24738, found 509.2480.

Example 8E Synthesis of2-tert-butyl-4-chloro-5-[4-(2-hydroxyethoxymethyl)benzyloxy]-2H-pyridazin-3-onehexadeuterate

To a solution of the product of Example 8D (330 mg, 0.677 mmol) in THF(7 mL) was added a 1M solution (in THF) of tetrabutylammonium fluoride(1 mL, 1.016 mmol) dropwise. The reaction was stirred at roomtemperature for 2 hours under nitrogen atmosphere, monitoring by TLC(1:1 hexane:ethyl acetate). The reaction was then concentrated underreduced pressure and passed through a thick pad of silica (100% ethylacetate) to obtain the product as an oil containing a minor percentageof the corresponding silanol. The material was taken to the next stepwithout further purification. ¹H NMR (600 MHz, CDCl₃): 7.72 (s, 1H),7.41 (s, 4H), 4.59 (s, 2H), 1.64 (s, 9H); ¹³C NMR (150 MHz, rt, CDCl₃):159.2, 153.9, 139.5, 134.5, 128.5, 127.5, 125.3, 118.6, 73.0, 66.6,28.1; HRMS calcd for C₂₅H₂₃D₆ClN₂O₆S: 549.169754, found 549.1705.

Example 8F Synthesis of toluene-4-sulfonic acid2-[4-(1-tert-butyl-5-chloro-6-oxo-1,6-dihydro-pyridazin-4-yloxymethyl)-benzyloxy]ethylester hexadeuterate

To a solution of the product of Example 8E (250 mg, 0.670 mmol) indichloromethane (7 mL) was added p-toluenesulfonyl chloride (153 mg,0.805 mmol), N,N-dimethylaminopyridine (DMAP, 98 mg, 0.805 mmol), andtriethylamine (140 μL, 1.005 mmol). The reaction was stirred at roomtemperature overnight under nitrogen atmosphere. Thin layerchromatography (1:1 hexane:ethyl acetate) indicated almost completeconsumption of the alcohol. The reaction was concentrated under reducedpressure and the crude material was purified by flash chromatography(2:1 hexane:ethyl acetate to 1:1 hexane:ethyl acetate to 100% ethylacetate) to recover the starting material (9 mg) and the product (261mg, 77% yield based on recovered starting material) as a clear oil. ¹HNMR (600 MHz, CDCl₃): 7.76 (d, 2H, J=8.3 Hz), 7.73 (s, 1H), 7.36 (d, 2H,J=8.1 Hz), 7.29 (m, 4H), 4.47 (s, 2H), 2.40 (s, 3H), 1.61 (s, 9H); ¹³CNMR (150 MHz, rt, CDCl₃): 159.0, 153.8, 145.0, 138.5, 134.4, 133.1,129.9, 128.1, 128.0, 127.3, 125.2, 118.1, 72.7, 71.0, 37.0, 63.4, 28.0,21.7.

Example 8G

To a solution of the product of Example 8F (14 mg, 0.027 mmol) inacetonitrile (300 μL) was added potassium fluoride (3.1 mg, 0.053 mmol)and K222 (20 mg, 0.053 mmol). The reaction was stirred at 90° C. for 10minutes under nitrogen atmosphere, monitoring by TLC (1:1 hexane:ethylacetate). The reaction was then cooled to room temperature andconcentrated under reduced pressure. The crude material was purified bypreparative TLC (2:1 hexane:ethyl acetate) to obtain the product as anoil (6.2 mg, 62% yield). ¹H NMR (600 MHz, CDCl₃): 7.70 (s, 1H), 7.40 (s,4H), 4.61 (s, 2H), 1.63 (s, 9H); ¹³C NMR (150 MHz, rt, CDCl₃): 158.5,153.1, 138.2, 133.8, 127.7, 126.8, 124.6, 117.8, 72.4, 65.9, 27.3; ¹⁹FNMR (564 MHz, CDCl₃): −225.2 (m, 1F).

Example 9 General Radiosynthetic and Purification Procedures forPreparation of Fenazaquin and Pyridaben Complexes Radiolabeled with theFluorine-18 Radionuclide

The Fluorine-18 (¹⁸F) used in these Examples was produced via the protonbombardment of enriched Oxygen-18 (¹⁸O) as H₂ ¹⁸O with approximately 10MeV protons by PETnet (Woburn, Mass.). The expression for this nuclearreaction is: O¹⁸(p, γ)¹⁸F.

For all of the radiosynthetic reactions, a similar procedure was used.All glassware was silanized to preclude adhesion of the material to thevessel walls and to optimize transfers. A dedicated, specific HPLC unitwas used for purification for all compounds. A dedicated specific HPLCunit was used for radioanalytical analyses of final product.

The ¹⁸F typically was received from the supplier deposited on aprocessed column (¹⁸F column) encased in lead shielding. The ¹⁸F columncontained the sodium salt coordinated to either alumina or a quaternaryammonium salt housed in a glass column. The column ends are connected toTygon™ tubing with male and female Luer™ lock fittings. The ¹⁸F wasremoved from the column using the following method.

1. A solution of 15 mg of potassium carbonate (K₂CO₃) in 1 mL ofdistilled/deionized water (H₂O) and a solution of 90 mg of4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane (Kryptofix™;K222) dissolved in 4 mL of anhydrous acetonitrile (CH₃CN) were combinedand gently stirred, ensuring the layers did not separate, forming thecolumn eluting solution (CES).2. A one mL aliquot of the CES was extracted from the vial described instep three using a 3 mL syringe and the syringe was attached to the maleLuer™ lock of the Tygon™ tubing connected to the ¹⁸F column.3. A narrow gauge needle was attached to the female Luer™ lock of theother Tygon™ tubing connected to the ¹⁸F column, and the needle wasinserted through the rubber septum fitted to a 15 mL 24/40 Pyrex™pear-shaped glass flask.4. The 15 mL pear shaped flask was vented with a needle and the flaskwas flushed with dry nitrogen. The flushing needle was connected to avacuum line and the flow adjusted such that CES was slowly drawn throughthe ¹⁸F column into the 15 mL pear-shaped flask.5. The vacuum and N₂ gas flow were adjusted such that the contents ofthe flask were reduced to dryness. Anhydrous CH₃CN (1 mL) was added viasyringe to the flask, using vacuum to drive the transfer. The vacuum andN₂ gas flow were balanced to remove the acetonitrile. This procedure wasrepeated twice, after which point the vacuum was removed.6. The contents of the flask were removed via syringe and theradioactivity was quantified. The ¹⁸F solution was used directly inradiolabeling syntheses.

The next steps describe the radiolabeling of the fenazaquin andpyridaben analogs with ¹⁸F. As noted above, these steps were repeatedfor each of the compounds. The following reaction scheme, whilespecifically illustrating the synthesis of a pyridaben analog, depicts arepresentative synthesis for all of the ¹⁸F-fenazaquin and pyridabenanalogs:

7. The toluenesulfonate ester precursor to the desired fenazaquin orpyridaben analog (2.5 mg) was dissolved in CH₃CN (0.5 mL) in a conicalsilanized 5 mL Wheaton™ glass vial with a magnetic stirring bar. Thevial was immersed in a oil bath heated at 90° C. The solution of the ¹⁸Fdescribed above was added to the reaction vial the resultant mixture washeated at 90° C. for 30 minutes.8. The contents were transferred to a 50 mL silanized round bottom flaskcontaining distilled/deionized water (25 mL), and the contents of theflask are removed via syringe, and deposited on a Waters™ Oasis HLB(hydrophilic-lipophilic balance) column, allowing unreacted fluoride andundesired salts to pass through with the eluate.9. The organic components were eluted from the column into a conical 5mL vial using dichloromethane, (3 mL, CH₂Cl₂). The eluant was purifiedvia preparative HPLC (Phenomenex LUNA C-18 column 250×10 mm, 5 uparticle, 100 A pore. gradient elution 90/10 H₂O/CH₃CN—CH₃CN). Theappropriate fractions were concentrated and analyzed for radiochemicalyield and radiochemical purity (analytical HPLC). The solution wasconcentrated to dryness in vacuo, and dissolved in the appropriatevolume of 10% ethanolic saline for injection and/or biological studies.

Example 10 Synthesis of2-tert-butyl-4-chloro-5-(4-(4-[(¹⁸F]-fluorobutyl)benzyl)-thio-3(2H)-pyridazinone

Aqueous ¹⁸F (16 mCi, 0.1 ml) was added to a vacutainer containing 5 μlof tetrabutylammonium hydroxide (40% wt sol. in water). The mixture wasconcentrated under nitrogen in an oil bath. Acetonitrile (250 μl) wasadded and the mixture was concentrated under nitrogen. 100 μl of THF wasthen added to the mixture followed by 5 mg of2-tert-butyl-4-chloro-5-(4-(4-toluenesulfonyloxy-butyl)benzyl)thio-3(2H)-pyridazinone.The mixture was then heated in an oil bath at 70° C. for 30 minutes. Theresulting mixture was then diluted with water, and applied to a C18Sep-Pak, eluting with acetonitrile to obtain the title compound.

Example 11 Synthesis of2-tert-butyl-4-chloro-5-(2-[¹⁸F]-fluoro-1-(4-tert-butylphenyl)-1-ethyl)oxy-3(2H)-pyridazinoneExample 11A Synthesis of (4-tert-butylphenyl)ethane 1,2 diol

To a 100 ml round bottom flask is added 20 ml tert butanol, 20 ml ofwater and 5.6 g of AD-mix-β. The solution is stirred and cooled to 0 C.tert-butyl styrene (0.64 g, 4 mmol) is added to the mixture and theresulting solution is stirred overnight at 0 C. Solid sodium sulfite (6g) is added and the mixture stirred for an additional 30 minutes. Thesolution is then extracted in ethyl acetate, washed with water anddried. The crude is then purified by flash chromatography (silica gel;ethyl acetate/hexanes) to afford the product.

Example 11B Synthesis of1-tert-butyldimethylsilyloxy-2-hydroxy-2-(4-tertbutylphenyl)ethane

(4-tert-butylphenyl)ethane 1,2 diol (0.5 g, 2.57 mmol) is dissolved inDMF in a

25 ml round bottom flask and to this were added imidazole (0.210 g, 3.09mmol) and tert-butyldimethylsilyl chloride (0.46 g, 3.09 mmol). Themixture is stirred for 6 hours after which it is extracted indichloromethane and the organic layer washed with water and dried.Purification by flash chromatography (silica gel; ethyl acetate/hexanes)affords the above mentioned product.

Example 11C Synthesis of2-tert-butyl-4-chloro-5-(2-tert-butyldimethylsilyloxy-1-(4-tert-butylphenyl)-1-ethyl)oxy-3(2H)-pyridazinone

To a solution of 2-tert-butyl-4,5-dichloro-3(2H)-pyridazinone (0.5 g,2.27 mmol) in DMF (10 ml) were added anhydrous cesium carbonate (0.74 g,2.27 mmol) and 1-tert-butyldimethylsilyloxy 2-hydroxy2-(4-tertbutylphenyl)ethane (0.7 g, 2.27 mmol). The mixture is stirredfor 2 hours at 70° C. and then cooled to room temperature and ethylacetate is added to it. The solution is then washed with water, driedand concentrated and the residue subjected to purification by flashchromatography (silica gel; ethyl acetate/hexanes) to give the abovecompound.

Example 11D Synthesis of2-tert-butyl-4-chloro-5-(2-hydroxy-1-(4-tert-butylphenyl)-1-ethyl)oxy-3(2H)-pyridazinone

A 25 ml round bottom flask is charged2-tert-butyl-4-chloro-5-(2-tert-butyldimethylsilyloxy-1-(4-tert-butylphenyl)-1-ethyl)oxy-3(2H)-pyridazinone(0.5 g, 1.01 mmol) and to it is added 5 ml of 1% concd. HCl in ethanol.The solution is stirred for one hour after which it is poured in waterand extracted with ethyl acetate. The ethyl acetate is removed using therotary evaporator and subjected to flash chromatography using silica geland ethyl acetate/hexanes mixture as the eluting medium.

Example 11E Synthesis of2-tert-butyl-4-chloro-5-(2-p-toluenesulfonyloxy-1-(4-tert-butylphenyl)-1-ethyl)oxy-3(2H)-pyridazinone

To a 15 ml round bottom flask charged with2-tert-butyl-4-chloro-5-(2-hydroxy-1-(4-tert-butylphenyl)-1-ethyl)oxy-3(2H)-pyridazinone(0.25 g, 0.66 mmol) is added pyridine. Toluenesulfonyl chloride (0.15 g,0.79 mmol) is then added to it and the mixture stirred for 4 hours. Thereaction mixture is diluted with ethyl acetate, washed with 5% coppersulfate solution and then with water and dried. After removing thesolvent on the rotary evaporator the crude is purified by flashchromatography using ethyl acetate-hexanes as the eluting mixture.

Example 11F Synthesis of2-tert-butyl-4-chloro-5-(2-fluoro-1-(4-tert-butylphenyl)-1-ethyl)oxy-3(2H)-pyridazinone

To a 15 ml round bottom flask charged with2-tert-butyl-4-chloro-5-(2-p-toluenesulfonyloxy-1-(4-tert-butylphenyl)-1-ethyl)oxy-3(2H)-pyridazinone(0.2 g, 0.375 mmol) is added 3.75 ml of tetrabutylammonium fluoridesolution (1M in THF, 3.75 mmol). The mixture is first stirred at roomtemperature for 15 minutes after which it is heated for 15 minutes at100° C. The solution is then cooled to room temperature and to it isadded dichloromethane followed by water. The layers were separated andthe organic layer is washed with water and then dried. The organic layeris then concentrated and subjected to purification using silica gelflash chromatography (ethyl acetate/hexanes) to obtain the abovecompound.

Example 11G Synthesis of2-tert-butyl-4-chloro-5-(2-[¹⁸F]-fluoro-1-(4-tert-butylphenyl)-1-ethyl)oxy-3(2H)-pyridazinone

Aqueous ¹⁸F (16 mCi, 0.1 ml) is added to a vacutainer containing 5 μl oftetrabutylammonium hydroxide (40% wt sol. in water). The mixture isconcentrated under nitrogen in an oil bath and 250 μl of acetonitrile isadded and this too is concentrated under nitrogen. 100 μl of THF is thenadded to it followed by 5 mg of2-tert-butyl-4-chloro-5-(2-p-toluenesulfonyloxy-1-(4-tert-butylphenyl)-1-ethyl)oxy-3(2H)-pyridazinone.The mixture is then heated in an oil bath at 70° C. for 30 minutes. Thisis then diluted with water, applied to a C18 Sep-Pak and eluted withacetonitrile to get the above mentioned compound.

Example 12 Synthesis of Fenazaquin Analogs Example 12A Synthesis of4-Chloro quinazoline

4-Quinazolone (5 g, 34.2 mmol), phosphorus pentachloride (10.26 g, 47.9mmol) and phosphorus oxychloride (40 ml) were refluxed for two hours at115-118C. The phosphorus oxychloride was removed in vacuo and theresidue was extracted in ether. The entire mixture was then poured intoa vessel containing crushed ice and again extracted with ether. Theether layer was then washed with sodium bicarbonate and dried. The etherwas then removed under reduced pressure and the crude material wasrecrystallized from hexanes to afford the product.

Example 12B Synthesis of 4-(4-Methylphenyl)butanol

To lithium aluminum hydride (427 mg, 11.2 mmol) suspended in dry ether(5 ml) at 0° C. is added 1 g of 4-(4-methylphenyl)butanoic acid (5.614mmol) dissolved in dry ether (10 ml) over a period of 30 minutes. Thereaction mixture is then allowed to warm to room temperature and stirredfor 4 hours. Water (0.43 ml), NaOH (15% solution, 0.43 g) and water(1.29 ml) were then added successively and the resulting solution isstirred for 30 minutes. The resulting precipitate is filtered and washedwith ether and dried. The filtrate is then concentrated and purified byflash chromatography using ethyl acetate-hexanes as the eluting medium.

Example 12C Synthesis of 4-(4-methylphenyl)butyl tert-butyldimethylsilylether

4-(4-Methylphenyl)butanol (0.5 g, 3.04 mmol) is dissolved in 5 ml DMFand to it is added imidazole (310 mg, 4.56 mmol) andtert-butyldimethylsilyl chloride (685 mg, 4.56 mmol). The reaction isstirred for 4 hrs after which it is extracted in ethyl acetate andwashed with water to remove all DMF. The organic layer is then dried andconcentrated. The crude mixture is then purified by flash chromatographyusing a mixture of ethyl acetate-hexanes as the eluting medium to affordthe above mentioned product.

Example 12D Synthesis of 4-(4-bromomethylphenyl)butyltert-butyldimethylsilyl ether

To a 50 ml round bottom flask is charged 4-(4-methylphenyl)butyltert-butyldimethylsilyl ether (0.25 g, 0.89 mmol), N-bromosuccinimide(0.158 g, 0.89 mmol), benzoyl peroxide (2.17 mg, 0.0089 mmol) and 10 mlcarbon tetrachloride. This mixture is refluxed overnight after which itis cooled and filtered. The filtrate is concentrated and the resultingcrude residue purified by flash chromatography in ethyl acetate-hexanesto afford the product.

Example 12E Synthesis of4-(4-tert-butyldimethylsilyloxybutyl)phenylacetic acid

4-(4-bromomethylphenyl)butyl tert-butyldimethylsilyl ether (0.2 g, 0.561mmol) in dry ether is added dropwise to Mg turnings (13.77 mg, 0.561mmol). A few crystals of iodine are then added to initiate the reactionand the mixture is refluxed overnight under nitrogen atmosphere. Thesolution is then cooled and CO₂ gas is bubbled into it for 10 minutes.Stirring is continued for a further 2 hours after which water is addedto the reaction mixture. The mixture is then extracted with ethylacetate, washed and dried. After removing the organic solvent underreduced pressure the crude is purified by flash chromatography (silicagel; ethyl acetate/hexanes) to yield the desired product.

Example 12F Synthesis of2-hydroxyethyl-4-(4-tert-butyldimethylsilyloxybutyl)benzene

4-(4-tert-butyldimethylsilyloxybutyl)phenylacetic acid (0.25 g, 0.775mmol) dissolved in dry ether is added dropwise to a suspension oflithium aluminum hydride in ether (44.2 mg, 1.16 mmol). The reactionmixture is stirred for 5 hours after which water (45 μl), NaOH (15%solution, 45 μl) and water (135 μl) are successively added and thereaction mixture is stirred for a further 30 minutes. The resultingprecipitate is filtered

and washed with ether. The ether filtrate is then washed with water anddried. After concentrating the ether, the product obtained is purifiedby flash chromatography (silica gel; ethyl acetate/hexanes).

Example 12G Synthesis of4-(2-(4-(4-tert-butyldimethylsilyloxybutyl)phenyl)ethoxy)quinazoline

2-hydroxyethyl-4-(4-tert-butyldimethylsilyloxybutyl)benzene (0.3 g, 0.97

mmol) is dissolved in dry tetrahydrofuran and to it is added sodiumhydride (24 mg, 1 mmol). The resulting solution is stirred at roomtemperature for 30 minutes after which 4-chloroquinazoline (0.164 g, 1mmol) is added to the above solution. The solution is then stirred for 6hours after which water is added to the mixture. The solution is thenextracted in dichloromethane. The organic layer is washed, dried andthen concentrated to yield the crude product which is purified by flashchromatography (silica gel; ethyl acetate/hexanes) to give the product.

Example 12H Synthesis of4-(2-(4-(4-hydroxybutyl)phenyl)ethoxy)quinazoline

To 4-(2-(4-(4-tert-butyldimethylsilyloxybutyl)phenyl)ethoxy)quinazoline(0.4 g, 0.916

mmol) is added tetrabutylammonium fluoride solution (1M TBAF in THF,4.58 ml, 4.58 mmol). The solution is stirred for 2 hours after whichwater is added to the reaction and this is extracted in ethyl acetate.The organic layer is then washed with water, dried and concentrated. Theresidue obtained is purified by flash chromatography (silica gel; ethylacetate/hexanes).

Example 12I Synthesis of4-(2-(4-(4-p-toluenesulfonyloxybutyl)phenyl)ethoxy)quinazoline

A 15 ml round bottom flask charged with4-(2-(4-(4-hydroxybutyl)phenyl)ethoxy)quinazoline (0.25 g, 0.77 mmol) isdissolved in pyridine (5 ml). p-Toluenesulfonyl chloride (0.15 g, 0.79mmol) is then added to it and the mixture stirred for 4 hours. Thereaction mixture is diluted with ethyl acetate, washed with 5% coppersulfate solution and then with water and dried. After removing thesolvent on the rotary evaporator the crude is purified by flashchromatography using silica gel (ethyl acetate/hexanes) to give theproduct.

Example 12J Synthesis of4-(2-(4-(4-fluorobutyl)phenyl)ethoxy)quinazoline

4-(2-(4-(4-p-toluenesulfonyloxybutyl)phenyl)ethoxy)quinazoline (0.3 g,0.63 mmol) is added to a solution of potassium fluoride/kryptofix 222 in5 ml THF (1:1 ratio, 3.15 mmol each). After stirring at room temperaturefor 15 minutes the solution is then refluxed for 20 minutes. It is thencooled and water is added to it. The solution is then extracted indichloromethane and washed with water and dried. The crude product ispurified by silica gel flash chromatography (ethyl acetate/hexanes) toafford the product.

Example 12K Synthesis of4-(2-(4-(4-[¹⁸F]-fluorobutyl)phenyl)ethoxy)quinazoline

To a 5 ml reaction vial containing 100 mCi of ¹⁸F in 300 mg of ¹⁸O wateris added

a 1 ml solution consisting of 10 mg of Kryptofix, 1 mg potassiumcarbonate, 0.005 ml water and 0.95 ml acetonitrile. The vial is heatedto remove all the solvents and dry acetonitrile (1 ml) is added to thevial. This is also removed by evaporation.4-(2-(4-(4-p-toluenesulfonyloxybutyl)phenyl)ethoxy)quinazoline (5 mg) inacetonitrile is then added to it. The vial is sealed and heated for 30minutes at 100° C. The mixture is diluted with dichloromethane andpassed through a Sep-Pak and eluted with tetrahydrofuran. The solvent isevaporated to get the above mentioned compound.

Example 13 Imaging with2-tert-butyl-4-chloro-5-[4-(2-[¹⁸F]fluoro-ethoxymethyl)-benzyloy]-2H-pyridazin-3-onein Normal Animals

Imaging was performed with a microPET camera (Focus220, MICROPET) inanesthetized rats, rabbits and nonhuman primates (NHP) following theintravenous administration of 1, 2 and 3 mCi of ¹⁸F labeled2-tert-butyl-4-chloro-5-[4-(2-fluoro-ethoxymethyl)-benzyloy]-2H-pyridazin-3-one,also referred to herein as Agent 2. After count acquisition, images wereconstructed and manually re-orientated as a series of tomographic views.FIG. 1 shows representative images of the (a) transverse, (b) coronal,and (c) sagittal planes of a brain, with2-tert-butyl-4-chloro-5-[4-(2-[¹⁸F]fluoro-ethoxymethyl)-benzyloy]-2H-pyridazin-3-onein a normal NHP. These images were acquired 30 minutes post injection(mpi) of 5.1 mCi of2-tert-butyl-4-chloro-5-[4-(2-[¹⁸F]fluoro-ethoxymethyl)-benzyloy]-2H-pyridazin-3-oneand were decay corrected. Intravenous injection of2-tert-butyl-4-chloro-5-[4-(2-[¹⁸F]fluoro-ethoxymethyl)-benzyloy]-2H-pyridazin-3-onedid not induce changes in heart rate and ECG waveforms and all animalssurvived the image acquisition period with no adverse effects. It isapparent by the uptake and resolution of the images that Agent 2 isefficiently transported into the brain, providing useful images for theassessment of mitochondrial density function and brain perfusion.

Example 14 Imaging with Various Contrast Agents in Nonhuman Primates

In this example, imaging studies were performed using the three contrastagents listed in Table 1 below.

TABLE 1 Contrast Agents utilized in imaging study. Agent Chemical NameChemical Structure 1 2-tert-butyl-4-chloro-5-[4-(4-[¹⁸F]Fluoro-butyl)-benzyloxy]-2H- pyridazin-3-one

2 2-tert-Butyl-4-chloro-5-[4-(2- (¹⁸F)fluoroethoxymethyl)-benzyloxy]-2H-pyridazin-3-one

3 2-tert-Butyl-4-chloro-5-[4-(3- (¹⁸F)fluoropropoxy)-benzyloxy]-2H-pyridazin-3-one

After anesthesia, about 1 mCi of Agent 2 or Agent 3 was injected into arat intravenously and the rat brain was imaged in a microPET scanner.Following the image acquisition, the images were reconstructed intotomographic views. FIG. 2A shows representative images of the transverse(left image) and sagittal (right image) sections of a rat brain imagedusing Agent 2, while FIG. 2B shows representative images of thetransverse (left image) and sagittal sections (right image) of a ratbrain imaged using Agent 3. The results suggest that, unlike Agent 3,Agent 2 is capable of passing the blood brain barrier and accumulatingin the brain.

Similarly, in nonhuman primates (NHP), about 3 mCi of Agent 1 or Agent 2was injected intravenously and the brain of NHP was imaged in amicroPET. FIG. 3A shows representative tomographic images of thetransverse (left image) and sagittal (right image) sections of a NHPbrain imaged using Agent 2, while FIG. 3B shows representativetomographic images of the transverse (left image) and sagittal sections(right image) of a NHP brain imaged using Agent 1. The NHP brain was notvisible when imaged with Agent 1. However, the NHP brain was visiblewhen imaged with Agent 2, indicating that Agent 2 is capable of passingthrough blood brain barrier and accumulating in the brain.

The structure-activity relationship (SAR) study described in thisexample indicate that the presence and/or position of a heteroatom(e.g., oxygen atom) in the side chain of the contrast agent can affectits ability to diffuse through blood brain barrier. While omission of aheteroatom in the side chain of Agent 1 increased the lipophilicity ofAgent 1 (Log P value: 4.84 vs. 2.73 of Agent 2 calculated withACD/ChemSketch v.11.02 software, Advanced Chemistry Development, Inc.,Toronto ON), it exhibited decreased penetration into the brain, relativeto Agent 2.

Example 15 Imaging with Agent 2 in Mouse Models of Tumor

Imaging studies using several mouse tumor models, including c-neu ONCOmice, nu/nu mice with OVCAR tumor, and nu/nu mice with HT1080 tumor,were conducted using contrast agents described herein. Afteradministering anesthesia to the mouse, about 500 μCi of Agent 2 (fromTable 1) were injected intravenously and the tumor was imaged in amicroPET scanner. After imaging acquisition, images were reconstructedinto tomographic views. FIG. 4 shows representative transverse (leftimage) and coronal (right image) images of a c-neu ONCO mouse, where thetumor was visible when imaged with Agent 2. In addition, tumor uptake ofAgent 2 was measured in the mouse models after imaging. The uptake wasdetectable in a range from 1-4% injected dose per gram tissue.

It will be evident to one skilled in the art that the present inventionis not limited to the foregoing illustrative examples, and that it canbe embodied in other specific forms without departing from the essentialattributes thereof. It is therefore desired that the examples beconsidered in all respects as illustrative and not restrictive,reference being made to the appended claims, rather than to theforegoing examples, and all changes which come within the meaning andrange of equivalency of the claims are therefore intended to be embracedtherein.

1. A method of imaging at least a portion of the central nervous system(CNS) in a subject, comprising: administering to the subject a contrastagent having a structure as in Formula (II),

wherein: J is selected from N(R²⁷), S, O, C(═O), C(═O)O, NHCH₂CH₂O, abond, or C(═O)N(R²⁷); K and L, when present, are independently selectedfrom hydrogen, alkoxyalkyl, alkyloxy, aryl, alkyl, heteroaryl, and animaging moiety, each of which is optionally substituted; M is selectedfrom alkoxyalkyl or alkyloxy, each of which is optionally substituted,or L and M, together with the atom to which they are attached, form aring, optionally substituted; Q is halo or haloalkyl; n is 0, 1, 2, or3; R²¹, R²², R²³, R²⁴, R²⁵, R²⁶, and R²⁷ are independently selected fromhydrogen, alkyl, optionally substituted, and an imaging moiety; R²⁹ isalkyl, optionally substituted; and Y is carbon or oxygen; provided thatwhen Y is oxygen, K and L are absent and M is alkoxyalkyl, optionallysubstituted, wherein at least one imaging moiety is present in Formula(II); and scanning the patient using diagnostic imaging to produce animage of at least a portion of the CNS.
 2. The method as in claim 1,wherein the method of imaging at least a portion of the CNS in thesubject comprises imaging perfusion in the brain of the subject.
 3. Amethod as in claim 1, wherein the image is used in the diagnosis of asubject.
 4. A method as in claim 3, wherein the diagnosis is a diagnosisof a CNS disorder or condition.
 5. A method as in claim 1, wherein theimage is used to determine the stage of a disease.
 6. A method as inclaim 5, wherein the disease is a CNS disorder or condition.
 7. A methodas in claim 1, further comprising selecting a treatment for a centralnervous system (CNS) disorder or condition in the subject based at leastin part on the image of at least a portion of the CNS of the subject. 8.A method as in claim 1, further comprising evaluating a treatment of acentral nervous system (CNS) disorder or condition in the subject basedat least in part on the image of at least a portion of the CNS of thesubject.
 9. A method as in claim 2, further comprising selecting atreatment of a central nervous system (CNS) disorder or condition in thesubject based at least in part on the image of at least a portion of thebrain.
 10. A method as in claim 2, further comprising evaluating atreatment of a central nervous system (CNS) disorder or condition in thesubject based at least in part on the image of at least a portion of thebrain. 11-16. (canceled)
 17. A method of imaging cancer in a subject,comprising: administering to the subject a contrast agent whichcomprises an imaging moiety and a compound bound to the imaging moiety,the compound selected from pyridaben, fenazaquin, a pyridaben analog, apyrimidifen analog, a tebufenpyrad analog, and an fenazaquin analog; andscanning the patient using diagnostic imaging to produce an image of atleast a portion of the cancer.
 18. A method as in claim 17, wherein theimage is used in the diagnosis of a subject.
 19. A method as in claim18, wherein the diagnosis is a diagnosis of a cancer.
 20. A method as inclaim 17, wherein the image is used to determine the stage of a cancer.21. A method as in claim 17, further comprising selecting a treatment ofa cancer in the subject based at least in part on the image of at leasta portion of the cancer.
 22. A method as in claim 17, further comprisingevaluating a treatment of a cancer in the subject based at least in parton the image of at least a portion of the cancer.
 23. A method as inclaim 17, wherein the cancer is a primary tumor or neoplasia.
 24. Amethod as in claim 17, wherein the cancer is a metastatic growth.
 25. Amethod as in claim 17, wherein the imaging moiety is a radioisotope fornuclear medicine imaging.
 26. A method as in claim 17, wherein theradioisotope for nuclear medicine imaging is ¹¹C, ¹³N, ¹⁸F, ¹²³I, or¹²⁵I. 27-69. (canceled)